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‘If we knew what it was we were doing, it would not be called research,  
would it? ‘ 
Albert Einstein 
(Died from a ruptured abdominal aortic aneurysm 18th April, 1955)
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ABSTRACT 
OBJECTIVE:  
Patients undergoing open repair of asymptomatic abdominal aortic aneurysms (AAA) 
demonstrate a prothrombotic state that initially deteriorates in the peri-operative period before 
improving beyond the pre-operative state. We hypothesised that a similar haemostatic 
improvement occurs following endovascular AAA repair (EVAR) and that the initial 
prothrombotic derangement may increase the risk of myocardial injury.  
 
METHODS:   
60 patients [57 men; median (IQR) age, 77 (72-82) years] underwent EVAR. Patients were 
assessed at baseline, 24-hours and 1-month post-procedure. Thrombin-antithrombin III-
complex (TAT), tissue-plasminogen activator (t-PA) and plasminogen activator inhibitor 
(PAI-1), and soluble (s) P-selectin levels were assessed as biomarkers of coagulation, 
fibrinolysis and platelet activity, respectively. Cardiac Troponin T (cTnT) levels were 
assessed as a biomarker of myocardial injury. 
 
RESULTS:   
An increase in sP-selectin levels occurred between baseline [median (IQR), 80.5(68-128) 
ng/ml], 24-hours [median (IQR), 89.5(73-112) ng/ml; p=0.003] and 1-month [median (IQR), 
110(89-143) ng/ml; p=<0.0001] post-EVAR. There was a trend towards increased TAT levels 
at 24-hours [median (IQR), 21.65(13-33.1) µg/l; p=0.069] compared to pre-operation [median 
(IQR), 7.15(4.7-31.3) µg/l] followed by a significant decrease at 1-month [median (IQR), 8.1 
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(5.4-14.85) µg/l; p=<0.0001].  cTnT levels were raised (>0.03ng/ml) in 16% of patients.  
There was a positive correlation between cTnT and TAT levels at 24 hours post-EVAR 
(r=0.38, p = 0.039, Kendall tau B = 0.26)  
 
CONCLUSION:  
These novel data suggest that the peri-operative pro-thrombotic state following EVAR may be 
associated with an increased risk of myocardial injury. 
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CHAPTER 1 
 
THE SHORT TERM EFFECTS OF ENDOVASCULAR ANEURYSM REPAIR (EVAR) ON 
COAGULATION AND CARDIOVASCULAR MORBIDITY AND MORTALITY IN PATIENTS 
WITH INFRA-RENAL ABDOMINAL AORTIC ANEURYSMS 
 
INTRODUCTION 
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1.1 BACKGROUND 
The incidence of abdominal aortic aneurysm (AAA), defined as an enlargement of at least 
3cm, increases with age and affects approximately 4% of the elderly general population (>65 
years) within the United Kingdom. The age-specific prevalence is six times greater in men 
than women with an estimated prevalence of 5-8% for men aged 65-80 years old. 1 2 3  The 
majority of abdominal aortic aneurysms affect the infra-renal aorta and 75% are 
asymptomatic at the time of presentation having been identified incidentally during routine 
health checks or investigations for other pathologies.   
The natural history of AAA is that of gradual accelerating, asymptomatic expansion until 
rupture occurs. The best-known predictor of rupture rate is the maximum AAA diameter; the 
annual risk of rupture for an aneurysm with a diameter greater than 6cm may be as high as 
25%. (See table 1.1) 
 
DIAMETER 5-YEAR RISK OF RUPTURE 
<5 cm 5% 
5-6 cm 25% 
6-7 cm 35% 
>7 cm 75% 
 
Table 1.1: AAA rupture rates based on maximum transverse diameter 4 
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Approximately 2500 men aged >60 years die as a result of a ruptured AAA in England and 
Wales per year; 2.5% of all deaths in males aged >60 years. Of these deaths approximately 
half occur prior to hospital treatment. 1 5 For patients who survive to reach hospital alive, 
despite advances in peri-operative management, in-hospital mortality rates following 
emergency open surgery for ruptured AAA remain devastatingly high. In our experience, 
open repair of rAAA is associated with an in-hospital mortality rate of 40%. 6 Therefore in the 
United Kingdom elective repair of an infrarenal abdominal aortic aneurysm, in a suitably fit 
patient, is recommended when the aneurysm measures >5.5cm, or greater than 4.5cm with a 
growth rate >0.5cm/six months. 4  
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1.2 ENDOVASCULAR INFRA-RENAL ABDOMINAL AORTIC ANEURYSM REPAIR (EVAR)  
Following the first reported endovascular infra-renal abdominal aortic aneurysm repair 
(EVAR) by Juan Parodi in 1990, EVAR has been widely promoted as a less invasive and 
safer alternative treatment option to conventional open AAA repair, especially in the high-risk 
patient. It is now well established following the publications of the UK EndoVascular 
Aneurysm Repair Trials 1 and 2 (EVAR-1 & EVAR-2) and the Dutch Randomised 
Endovascular Aneurysm Management (DREAM) trial that elective endovascular repair of an 
AAA reduces peri-operative mortality by approximately 3% compared with open surgical 
repair in the fit and anatomically suitable patient. 7 8 9 10 However exponents have argued that 
these initial operative mortality benefits are offset by the long-term economic cost due to late 
graft-related complications.13  
Endoleak is a complication unique to EVAR and results in perfusion of the aneurysm sac and 
subsequent risk of rupture. (See appendix 1) The EVAR-1 trial reported 22% (118 cases) of 
EVARs were complicated by endoleak and 35% require a secondary procedure to maintain 
complete aneurysm exclusion within 3 years of the procedure. 7 A systematic review by Drury 
et al reported 17.5% and 21.3% of all EVARs demonstrate endoleak at 30 days and 12 months 
respectively. 11 However, the endoleak rate is influenced by a variety of factors including pre-
procedural planning, type of stent graft deployed, aortic morphology and technical expertise. 
12   For these reasons, and the risk of other stent-related complications including stent 
migration, regular outpatient follow-up with computed tomographic aortography (CTA) is 
necessary to identify aneurysm exclusion failure. Thus, the short-term peri-operative 
mortality/morbidity benefits of EVAR may be outweighed by its long-term morbidity in 
terms of re-intervention as well as the associated economic burden. 11 13 
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Currently a number of different approaches have been instigated to reduce the economic cost 
of EVAR in order to maximise its short-term benefit. A number of institutions have adopted 
serial USS and plain radiographs instead of computed tomography as a means of graft 
surveillance. This requires dedicated ultrasonographers thereby potentially restricting follow-
up to a specific centres, and continues to pose a significant long-term burden on an 
institution’s resources.  Thus alternative, less onerous, methods of identifying stent-graft 
failure, and specifically endoleak, would be desirable.   
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1.3 ENDOVASCULAR ANEURYSM REPAIR AND HAEMOSTASIS 
It is reported that patients with asymptomatic AAA demonstrate a hypercoagulable and 
hypofibrinloytic state. 28  It is speculated that the pre-operative haemostatic derangement and 
subsequent improvement following open repair represents activation of the coagulation 
system by intraluminal aneurysmal sac thrombus. This would correlate with reports of a 
positive relationship between the size of the aneurysm sac thrombus and the extent of the 
haemostatic derangement. 14 Previous work by our research group has demonstrated an 
attenuation of the prothrombotic diathesis evident in patients affected by AAA follows open 
repair; Adam et al reported that elective open repair of AAA is associated with intense 
thrombin generation and inhibition of systemic fibrinolysis that is present pre-operatively and 
persists until day-2 peri-operatively where upon it largely resolves. 29 There are currently no 
robust studies investigating the effect of EVAR on the hypercoagulable and hypofibrinolytic 
state observed in these patients.  
Recently there has been interest in utilising changes in circulating levels of biomarkers as an 
alternative means of identifying stent-graft failure following EVAR. Two separate studies 
report circulating levels of metalloproteinase-3 and -9 (MMP-3 & MMP-9) as being 
significantly elevated in patients affected by AAA and successful EVAR has been shown to 
be associated with a decrease in MMP levels. 15 16 The presence of an endoleak and aneurysm 
sac pressurisation may cause an increase in MMP levels. To date only one study has 
investigated a biomarker of thrombin generation and degradation as a marker of stent-graft 
failure. Serino et al reported elevated levels of D-dimer in patients with type-1 endoleaks and 
stable/increasing sac diameters compared with patients who had endoleaks and decreasing sac 
diameters. 17 However, this study has limited value due to methodology deficiencies and lack 
of study power. No studies have investigated the use of modern biomarkers of coagulation, 
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fibrinolysis and platelet function as an alternative/complementary method of identifying 
patients with endoleak.  
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1.4 ENDOVASCULAR ANEURYSM REPAIR AND MYOCARDIAL INJURY 
Elective open infrarenal AAA repair is associated with a peri-operative mortality rate of 3-
10%. 18 19 20 21 22  Previous work from this institution has demonstrated that over one-quarter 
of patients undergoing elective open AAA repair suffer peri-operative myocardial injury as 
determined by raised cardiac troponin (cTn) levels. 23 Furthermore, similar haemostatic 
derangements to those reported by Adam et al are known to be independently associated with 
myocardial injury, stroke and multiple organ failure. 24 25 26 27 Thus, the majority of peri-
operative mortality following elective open AAA repair may be secondary to micro- and 
macro- vascular thrombosis causing myocardial injury, thromboembolism and multiple organ 
failure. 28 29  While a positive association between the peri-operative hypofibrinolytic state 
and myocardial injury has been demonstrated in patients undergoing emergency open repair 
of ruptured AAA, to date, the relationship between coagulation and fibrinolysis and 
myocardial injury after EVAR has not been studied. 30  
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1.5 HYPOTHESIS AND AIMS 
We hypothesise that following successful aneurysm sac exclusion by EVAR the underlying 
hypercoagulable state witnessed in these patients will be attenuated as a result of exclusion of 
the intraluminal thrombus from the systemic circulation. Furthermore, we speculate the re-
establishment of aneurysm sac perfusion secondary to an endoleak results in the re-
establishment of the pre-operative prothrombotic state secondary to exposure of the sac 
thrombus to the systemic circulation.  We speculate that the novel use of biomarkers of 
haemostasis can provide endoleaks in patients with EVAR.  
 
The aims of this thesis are to:  
1. Establish if intra-luminal thrombus volume is related to the pro-thrombotic diathesis 
evident in patients affected by AAA.  
2. Investigate changes to the resting pro-coagulant and hypofibrinloytic state following 
elective endovascular aneurysm repair for an asymptomatic infra-renal AAA. 
3. Investigate and correlate any peri-operative haemostatic changes with peri-operative 
myocardial injury. 
4. Accumulate pilot data on which to base future studies pertaining to the use of 
haemostatic biomarkers as a method of identifying endoleak. 
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1.3 SUMMARY 
The proposed study is, to the best of our knowledge, the first to investigate changes to 
coagulation, fibrinolysis and platelet activity following EVAR for infra-renal AAA. The study 
will not only attempt to corroborate previously published findings regarding open AAA 
repair, namely that successful aneurysm sac exclusion attenuates the resting hypercoagulable 
state in patients with AAA, but will extend our investigation to patients that suffer endoleaks. 
The proposed study will, therefore, attempt to determine if EVAR attenuates the 
hypercoagulable state in patients with AAA thereby providing a scientific foundation to base 
future investigation into whether or not an endoleak results in the re-establishment of this pro-
thrombotic diathesis. 
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CHAPTER 2 
 
AN OVERVIEW OF THE NORMAL COAGULATION AND FIBRINOLYTIC SYSTEMS 
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2.1 PLATELET ACTIVATION AND THE COAGULATION CASCADE 
Normal haemostasis represents a complex interaction between the damaged vessel wall, 
circulating cells (platelets and leukocytes) and circulating proteins/zymogens (coagulation 
factors). Injury to the vessel wall is the major stimulus for coagulation and results in the 
activation of endothelial cells and exposure of sub-endothelial collagen to circulating 
platelets. The activated endothelial cells express P-selectin on their surfaces and release von 
Willebrand factor (vWF) which aids in the localisation of thrombus formation at the site of 
injury. 31  Tissue factor (TF) is also released from the endothelium and plays a vital role in the 
activation of the coagulation cascade through the extrinsic pathway. Platelets bind to the 
exposed sub-endothelial collagen resulting in their activation and creation of a platelet plug. 
This is mediated by vWF which binds to both platelet membrane glycoprotein (Gp) Ib! 
receptor and sub-endothelial collagen. 32 Fibrinogen and vWF binds to Gp-IIb and Gp-IIIa 
receptors on adjacent platelets creating a lattice (aggregation) of platelets. 33 Activated 
platelets shed the contents of their stored !-granules and dense bodies (platelet granules), 
which include vWF, TF, adenosine diphosphate (ADP) and coagulation zymogens receptors. 
Activated platelets also undergo a morphological change from spherical to stellate that assists 
in the assembly of coagulation factors on their surface. (See figure 2.1.1) 
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Figure 2.1.1: Platelet activation and aggregation at the site of endothelial cell injury. (TF = 
tissue factor, ADP = adenosine diphosphate, vWF = von Willebrand factor, Fib. = fibrinogen) 
 
The formation of thrombin (Factor IIa) is vital to ensure stability of the initial platelet plug 
through its ability to convert fibrinogen to fibrin. 34 The formation of fibrin is achieved 
through activation of the coagulation cascade predominantly through the extrinsic pathway by 
the release of TF from endothelial cells and activated platelets. TF complexes and activates 
the zymogen factor VII (TF-FVIIa). This greatly enhances the catalytic ability of FVII which 
activates factors IX and X. Through a cascade effect that occurs on the surface of the 
activated platelets, the production of thrombin (factor IIa) occurs (See figure 2.1.2). Initially 
only trace amounts of thrombin are generated, however through a process of feedback 
amplification exponentially increasing amounts of thrombin are generated with each feedback 
loop. 35 Thrombin acts upon fibrinogen to create fibrin monomers, which in the presence of 
FXIIIa undergo polymerisation to form fibrin that strengthens and stabilises the plug. 36  
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Figure 2.1.2: Coagulation Cascade.  Biomarkers described in chapter 3 are highlighted in 
red. (Plt= platelets, sP-selectin= soluble P-selectin, vWF= von Willebrand factor, TF= tissue 
factor, APC-PCI=activated protein C-protein C inhibitor complex, PS= protein s, APC= 
activated protein C, TM-IIa= thrombomodulin-thrombin complex, TAT= Thrombin-
antithrombin complex, ATIII= antithrombin III, F1+2= prothrombin fragments 1 & 2, FM-F= 
fibrin monomer=fibrinogen complex)
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2.2 ANTICOAGULANTS AND FIBRINOLYSIS 
Diffuse intravascular thrombosis is prevented by the actions of localised and systemic 
anticoagulants and fibrinolytic mechanisms: 
2.2.1 Anticoagulants 
The two main natural anticoagulants are Antithrombin (AT) III and activated protein C 
(APC). AT III is the central physiological anticoagulant and prevents the coagulation cascade 
amplificatory effects of thrombin; these include the cleavage of fibrinogen to form fibrin, the 
activation of factors V and VIII and the mediation of platelet activation and aggregation. 
Thrombin binds to a receptor (thrombomodulin) presented on the surface of intact 
endothelium to form a thrombin-thrombomodulin complex that activates protein C as well as 
inhibiting the effects of thrombin. APC in the presence of its co-factor protein S acts as an 
anticoagulant through its ability to inactivate Factors Va and VIIIa. 37 38 In addition APC 
heightens fibrinolysis through two major mechanisms: APC forms a tight complex with 
plasminogen activator inhibitor type-1 (PAI-1) thereby preventing its inhibitory effect on 
tissue plasminogen activator (t-PA), secondly through its ability to limit thrombin generation 
it reduces the activation of thrombin activatable fibrinolysis inhibitor (TAFI). 39 40 Tissue 
factor pathway inhibitor (TFPI)/lipoprotein-associated coagulation inhibitor also acts as a 
reversible anticoagulant through its ability to complex to and inactivate factor Xa. TFPI-Xa 
complex also has the ability to inhibit factor TF-VIIa complex thereby arresting the extrinsic 
pathway. 41!
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2.2.2 Fibrinolysis 
Plasmin is the main fibrinolytic enzyme formed by the activation of the zymogen 
plasminogen through a variety of mechanisms. The main activator of plasminogen is t-PA 
which is produced by the vascular endothelium in response to thrombin. When incorporated 
into a forming clot t-PA is a potent catalyst for conversion of plasminogen to plasmin. 42 (See 
figure 2.2.1) 
 
 
 
 
Figure 2.2.1: Diagrammatic representation of the fibrinolytic pathway. Biomarkers described 
in chapter 3 are highlighted in red. (t-PA= tissue plasminogen activator, PAI-1= plasminogen 
activator inhibitor type-1, FDP= fibrinogen degradation product, PIC= !2-plasmin inhibitor 
complex, IIa= Thrombin)   
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Urokinase-type plasminogen activator, APC and factors XIa, XIIa and Kallikrein can also 
independently activate plasminogen. Plasmin degrades polymerised fibrin to form fibrin 
degradation products (fragment E and D-Dimer). The activation of plasminogen and fibrin 
degradation by plasmin is finely balanced by PAI-1 and TAFI. PAI-1 is released by the 
vascular endothelium in response to thrombin and inhibits t-PA. TAFI eliminates 
plasminogen receptor sites on partially degraded fibrin and thus slows the binding and 
activation of plasminogen and thus fibrinolysis. 42 !-Antiplasmin is also an inhibitor of 
plasmin.  
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2.3 SUMMARY 
Haemostasis requires the interaction of platelets, coagulation factors and fibrinolytic factors. 
Platelet and endothelial cell activation at the site of injury initiates clot formation. The 
coagulation cascade is activated predominantly through the extrinsic pathway to form fibrin, 
which is vital in creating a stable platelet plug. The fibrinolytic and anticoagulant systems 
ensure thrombus formation is limited to the site of vascular injury.  
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CHAPTER 3 
 
THE IMPACT ON BLOOD COAGULATION, FIBRINOLYSIS AND PLATELET 
ACTIVATION OF OPEN SURGICAL AND ENDOVASCULAR ANEURYSM REPAIR 
(EVAR) IN PATIENTS WITH INFRA-RENAL ABDOMINAL AORTIC ANEURYSMS 
 
A REVIEW OF THE LITERATURE 
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3.1 INTRODUCTION 
Major surgery causes a pro-thrombotic derangement in the peri-operative period with elevated 
levels of Factor VIII, Fibrinogen, Thrombin-antithrombin III-complex (TAT), von Willebrand 
Factor (vWF), deranged fibrinolysis and platelet hyperactivity. 43 44 45 46 47 48 49  
Patients undergoing elective open surgical infra-renal AAA repair have an associated 
operative mortality rate of 3-10%. 19 18 20 21 22 The majority of deaths are due to tissue damage 
and ischaemic-reperfusion injury, which result in an extensive and uncontrolled inflammatory 
response with micro- and macro- vascular thrombosis that may cause myocardial injury, 
thromboembolism and multiple organ failure. 29 50  
Endovascular abdominal aortic aneurysm repair (EVAR) provides a less invasive and safer 
alternative treatment to open surgical repair in the fit and anatomically suitable patient. The 
EVAR-1, EVAR-2 and DREAM trials reported EVAR was associated with a 60% reduction 
in peri-operative mortality when compared to open surgical repair. 7 8 9 10 These 
improvements may relate to an attenuation of the inflammatory response and pro-thrombotic 
diathesis associated with open repair through a reduction in tissue damage and ischaemic-
reperfusion injury. However Swartbol et al have reported EVAR as promoting a systemic 
inflammatory response equal to if not in excess of that witnessed after open repair.  51 This 
has been hypothesised to be secondary to cytokine release from the aneurysm sac thrombus as 
a result of introducer and catheter manipulation.  51 52 The use of contrast media has also been 
reported to induce arterial endothelial damage.  53 54  
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3.2 AIMS 
The aim of this chapter is to review and compare the effects of abdominal aortic aneurysm, 
open surgical repair and EVAR on coagulation, fibrinolysis and platelet activation as reported 
in the English-language scientific literature at the time of starting this thesis. 
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3.3 METHODS 
We performed a MEDLINE, EMBASE and Cochrane Central Register of Controlled Trials 
(CENTRAL) databases search looking for English-language articles between January 1970 
and August 2006 relating to abdominal aortic aneurysm, open surgical repair and EVAR, and 
their effects on haemostatic mechanisms. The terms coagulation, clotting, fibrinolysis, 
thrombosis and platelets were included amongst others. These were linked with terms such as 
abdominal aortic aneurysm, open repair, endovascular aneurysm repair and EVAR. Further 
articles were identified by following MEDLINE links, by cross-referencing from the 
reference lists of major articles and by following citations for these studies. Studies were 
specifically rejected if a) patient cohort was less than seven and b) values of assessed 
biomarkers of haemostasis were not included in the presented results. The studies were then 
graded and prioritised according to the level of the evidence presented.  
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3.4 RESULTS 
Studies examining the effect of AAA and open surgical or EVAR on blood coagulation, 
fibrinolysis and platelet activity are summarised in Tables 3.4.1-5. The coagulation cascade 
and fibrinolysis pathways are summarised in figures 3.4.1 and 3.4.2 
 
3.4.1 Effect of abdominal aortic aneurysm on haemostasis 
AAA represents a chronic inflammatory pathology and is usually characterised by the 
presence of mural thrombus directly proportional to the maximum AAA diameter. 55  In 
contrast to atherosclerotic occlusive disease, blood flow is maintained through the mural 
thrombus thereby providing an interface for exchange between the systemic circulation and 
thrombus.  The structure of the thrombus is highly complex with a network of inter-
connecting canaliculi capable of delivering macromolecules between the intra-luminal and 
thrombus-arterial wall surfaces. 56  The canaliculi often contain cellular infiltrates including 
neutrophils, macrophages and platelets, often in state of degranulation. This may lead to 
consumption of platelets and coagulation factors such that in this group of patients a sub-
clinical state of disseminated intravascular coagulation (DIC) may exist. 57  Thus the mural 
thrombus represents a biologically active entity with the ability to trap polymorphonuclear 
leukocytes, absorb circulating plasma components and aggregate platelets as well as being a 
source of proteolysis and fibrinolytic activity thought to be implicit in AAA progression. 56 58 
59 Several prospective comparative studies have examined the effects of AAA on direct and 
indirect biomarkers of thrombin generation, fibrinolysis and platelet activity. (See tables 
3.4.1-3).  
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Table 3.4.1:  Summary of studies investigating the association between AAA and levels of 
fibrinogen and biomarkers of fibrinolysis. (* symptomatic unruptured AAA, ** 
manufacturer’s range, *** t-PA activity)  
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Table 3.4.2:  Summary of studies investigating the association between AAA and biomarkers of thrombin generation. (* symptomatic  
unruptured AAA, ** manufacturer’s range) 
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Table 3.4.3:  Summary of studies investigating the association between AAA and vWF, Platelet count and sP-Selectin.  (* symptomatic 
unruptured AAA, ** manufacturer’s range) 
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Biomarker Study 
Maximum 
diameter of 
AAA 
Worst angle 
along length of 
AAA 
Maximum 
thickness of 
intraluminal 
AAA thrombus 
Total Intra-
luminal AAA 
thrombus 
volume 
APC-PCI Kolbel et al85 r=0.22, p=0.001     r=0.123, p=0.142 
Shindo et al69 r=0.208, p=NS     r=0.208, p=NS 
D-Dimer 
Yamazumi et al14 r=0.644, p=0.0001 r=-0.411, p=0.009 r=0.650, p=0.0001   
F-TFPI Yamazumi et al14 r=0.408, p=0.016 r=-0.583, p=0.0006     
Shindo et al69 r=0.208, p=NS     r=0.171, p=NS 
FDP 
Yamazumi et al14 r=0.561, p=0.0009   r=0.513, p=0.0024   
FM-FC Hosaka et al70 r=0.128, p=0.381   r=0.233, p=0.125   
PIC Yamazumi et al14 r=0.413, p=0.0146   r=0.484, p=0.042   
TAT Yamazumi et al14 r=0.566, p=0.001 r=-0.366, p=0.0305 r=0.677, p=<0.0001   
 
Table 3.4.4:  Summary of studies investigating the association between AAA morphology and biomarkers of haemostasis. 
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Table 3.4.5:  Summary of studies investigating the effects of open surgery on biomarkers of haemostasis.  [* Manufacturer’s range, ** 
mean follow up of 26 month (19-37)] 
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An elevated level of plasma fibrinogen is an independent risk factor for stroke and myocardial 
infarction as well as cardiovascular mortality. 60 61 62 An association between elevated 
fibrinogen and atherosclerotic peripheral vascular disease has been widely reported and 
elevated levels of plasma fibrinogen are found in patients who subsequently develop 
peripheral artery disease. 24 61 63 64 The association between non-ruptured AAA and plasma 
fibrinogen levels have been extensively investigated. 14 18 65 66 67 68 69 70 71 72 73 74  (See table 
3.4.1) Six from twelve studies have reported significantly elevated levels of fibrinogen in 
patients with asymptomatic AAA. Singh et al reported significantly increased levels of 
plasma fibrinogen in patients with AAA. 68  On multivariate analysis Lee et al reported an 
independent association between AAA and plasma fibrinogen (p=0.05, OR=1.51). 72 While 
Singh et al reported similar findings but only in the studies male cohort; male (p = <0.001, 
OR = 1.42) vs. females (p = 0.18, OR = 1.23). 68  
Hosaka et al reported elevated levels of both fibrinogen and fibrin-monomer-fibrinogen (FM-
F) complex in patients with AAA indicating increased thrombin activity. During the cleavage 
of fibrinogen by thrombin fibrinopeptide A and B are released to create fibrin monomer (FM) 
that undergoes polymerisation –catalysed by factor XIIIa- to form insoluble fibrin clots. 75 
When a pro-thrombotic state exists and thrombin generation is high FM forms soluble 
complexes with fibrinogen (FM-F complex) due to excess plasma fibrinogen. 76 Thus elevated 
levels of FM-F represent heightened thrombin activity. Furthermore, a sufficiently elevated 
concentration of FM-F may itself add to the pro-thrombotic diathesis as it precipitates from 
plasma. 76    
Adam et al reported significantly elevated levels of plasma fibrinogen in patients with 
symptomatic, but non-ruptured AAAs. 71 In a separate study, the same group reported no 
difference in pre-operative plasma fibrinogen levels between those patients with ruptured 
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AAA and asymptomatic, non-ruptured AAA (median (range), 2.27 (0.86-3.75) vs. 2.8 (1.59-
6.02) g/l, p = NS). 29 However, these studies involved small numbers of patients. 
Ten studies were identified investigating the association between AAA and fibrinolysis. 14 65  69 
70 71  72 73 77 78 79  (See table 3.4.1) Nine studies assessed the impact of AAA on plasma D-dimer 
levels. The degradation of fibrin by plasmin ultimately results in the formation of two 
fragment-D molecules that covalently link to form a dimmer: D-dimer. Thus the presence of 
D-dimer in the circulation represents ongoing clot formation and fibrinolysis. All studies 
report elevated levels of plasma D-dimer in patients with AAA indicating ongoing clot 
formation and fibrinolysis. On multivariate analysis Lee et al (p = <0.001, OR = 3.75) 
reported an independent association between circulating D-dimer levels and AAA. 72  
Tissue Plasminogen Activator (t-PA) is released from vascular endothelium in response to 
thrombin generation and becomes incorporated into the forming fibrin clot. When bound to 
fibrin t-PA is a potent activator of plasminogen and is therefore a marker of fibrinolysis. PAI-
1 is also released from the vascular endothelium in the presence of thrombin and acts to 
maintain a balance between clot formation and lysis by inhibiting t-PA. Four studies have 
reported the effect of AAA on both D-dimer levels and t-PA and/or Plasminogen Activator 
Inhibitor-1 (PAI-1). 65 71 72 77 All three studies reporting t-PA antigen levels found no difference 
in circulating levels in patients with or without an AAA. However, t-PA antigen levels reflect 
both the unbound, active t-PA and the bound, inactive t-PA/PAI-1 complexes. Therefore it is 
important to measure t-PA activity as opposed to t-PA antigen to avoid the paradox in which 
elevated levels of t-PA antigen are associated with a pro-coagulant state due to increase PAI-1 
activity. 29 Only one study has analysed both t-PA antigen and PAI-1 activity levels and 
reports no significant difference compared to their control populations although elevated D-
dimer levels in the AAA cohort was found. 77 Adam et al are the only group to report on t-PA 
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activity levels that were found to be comparable to the manufactures normal reference range 
as was PAI-1 activity in symptomatic, non-ruptured AAA. 71 
Thrombin plays an intricate part in coagulation initiation and platelet activation. More 
recently thrombin has been implicated in smooth muscle cell mitogenesis, with intimal 
vascular smooth muscle cells showing increased thrombin receptor expression. 80  The 
conversion of prothrombin to thrombin by prothrombinase complex results in the production 
of a degradation product with a half life of <90 mins; prothrombin fragment 1+2 (F1+2). 81 
Thrombin released through this enzymatic process is inactivated by antithrombin-III to form a 
Thrombin-antithrombin III-complex (TAT). 82 Thus, F1+2 and TAT are biomarkers of 
coagulation activation and thrombin generation.   This review identified six studies that 
reported on the effect of AAA on the levels of one or both of these biomarkers. 14 70 71 73 77 78  
(See table 3.4.2) All studies reporting TAT found elevated circulating levels in patients 
affected by AAA. Holmberg et al report elevated levels of TAT, but normal levels of F1+2. 77 
This may be explained by the short half-life of F1+2; elevated TAT levels are more indicative 
of ongoing thrombosis whereas F1+2 may be more reflective of a single acute thrombotic 
event.  
Activated protein-C (APC) is a natural anticoagulant and is produced on the surface of intact 
endothelium following the binding of thrombin to the endothelial cell cofactor: 
thrombomodulin. 83 APC in the presence of protein-S cofactor reduces Xase and 
prothrombinase activity through its ability to cleave factors Va and VIIIa, thereby limiting 
thrombin production to the site of endothelial injury. 37 38 APC is inactivated through binding 
to protein-C inhibitor (PCI) to form APC-PCI complex. This complex is detectable in the 
blood for <20 minutes after formation and is an indicator of thrombin generation. 84 Kolbel et 
al report a three-fold increase in median APC-PCI complex levels in patients with AAA when 
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compared to healthy controls (p = <0.0001), indicating that patients with AAA would appear 
to undergo periods of acute thrombus formation on background of chronically increased 
thrombin generation. 85   
Adhesion of platelets to exposed sub-endothelial collagen leads to platelet activation and 
aggregation. Von Willebrand Factor (vWF) through its platelet receptor Glycoprotein-1b (GP-
1B) mediates this interaction. 32 These activated platelets release prothrombotic mediators 
form dense bodies and alpha-granules that include vWF, adenosine diphosphate (ADP) and 
Thromboxane-A2 (TxA2). They are also rich in FVa and FVIIa receptors and undergo 
aggregation by the binding of fibrinogen to platelet GP-IIb/-IIIa receptors on adjacent 
platelets. 33 Thus, the central role of platelet-vessel wall interaction is the initiation and 
progression of thrombosis. Six studies report on the effects of AAA on platelets. 14 67 69 71 73 86 
Three of six studies reports significantly lower levels of platelets in patients with AAA. Milne 
et al, in addition to finding a lower a platelet count, reported elevated levels of Glycocalicin, a 
biomarker for GP-1B levels and suggested that this represented increased activation and 
destruction of platelets as a result of adherence and incorporation into the thrombus mass. 86  
This would appear to be supported by Mukaiyama et al who demonstrated uptake of 
radiolabelled platelets by the AAA lumen. 87  Platelets activated through exposure to sub-
endothelial collagen without concomitant aggregation at the site of injury are removed from 
the circulation by the reticulo-endothelial system irrespective of platelet age. 88 Thus the 
aneurysm thrombus mass may also induce platelet activation without platelet adhesion 
leading to their subsequent destruction and GP-1B release. Blann et al demonstrated increased 
levels of soluble P-selectin, a marker of platelet activation, and vWF in AAA patients, which 
would lend support to the theory of increased platelet activation. 67  
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3.4.2 Association between AAA morphology and haemostasis 
Three studies have reported on the correlation between AAA maximum diameter and 
thrombus volume, and markers of haemostasis. 14 69 70 (See table 3.4.4). AAA size and total 
volume/maximum thrombus thickness appear to correlate with the aforementioned changes in 
thrombin generation and fibrinolysis. Yamazumi et al reported a correlation between AAA 
tortuosity and markers of thrombosis. 89 This association may represent the association 
between blood flow velocity changes, particularly turbulent flow, and red blood cell (RBC) 
activation.  Shindo et al reported a correlation between RBC counts and the AAA lumen 
volume. 69 Activated RBCs release ADP resulting in platelet aggregation and activation. 90 
Thus the consumptive coagulopathy, resulting from the thrombus mass and the abnormal flow 
field in a tortuous lumen may both contribute to the haemostatic derangement reported in 
patients with AAA. 
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3.4.3 Effect of open surgical repair on biomarkers of haemostasis 
Major surgery is known to produce a pro-thrombotic derangement in the peri-operative period 
with raised levels of FVIII, Fibrinogen, TAT, vWF, platelet hyper-activity, and evidence of 
deranged fibrinolysis. 43 44 46 47 48 49 91 Patients undergoing major lower limb arterial 
reconstructive surgery exhibit defective endogenous fibrinolytic activity: increased levels of 
PAI-1 and t-PA antigen that return to pre-operative levels by one week post-procedure 
suggestive of a consumptive hypofibrinolytic state.  92 93 94   
Studies reporting the effect of open surgical AAA repair on haemostasis are summarised in 
table 3.4.5.  Yamazumi et al reported a significant decrease in circulating levels of TAT and 
D-dimer at 3-months post repair when compared to pre-operative levels (p = <0.01). 14 
However, the levels remained elevated when compared to those of the control group (p = 
<0.01) suggestive of ongoing up-regulation of thrombin generation and lysis. Holmberg et al 
reported similar findings with significantly elevated levels of TAT and F1+2 reported peri-
operatively which returned to pre-operative levels by one-week post surgery, but once again 
remained elevated compared to age-matched controls. 77 In a separate study the same group 
reported open surgical repair attenuating the pre-operative thrombotic derangement in the 
long term with a reduction in TAT and D-dimer plasma levels at a median follow up of 26 
months. 66 However, the values remained slightly higher than the normal healthy reference 
ranges suggesting that there was ongoing haemostatic derangement despite thrombus volume 
reduction.  
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3.4.4 Effect of EVAR on biomarkers of haemostasis 
To date only two studies has investigated the effect of EVAR on haemostasis. 17 95 Serino et al 
report the short-term effects of EVAR on circulating D-dimer levels in nine patients assessed 
pre-operatively and on day four post-operatively. D-dimer levels were elevated in seven 
patients and decreased in two patients. The median level for the entire patient cohort did not 
demonstrate a statistically significant difference between baseline and day four post-operation 
[563+/-521 ng/ml vs. 799+/-443 ng/ml (p = 0.19)]. This lack of statistical significance may 
represent a type-II error due to the study’s lack of power. Odegard et al reported increased 
platelet activation following the administration of contrast media intra-operatively and this 
remained increased during variable lengths of hospital stays. 95 
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3.5 DISCUSSION 
AAA is associated with increased thrombin generation, activity and fibrin turnover as 
demonstrated by increased plasma levels of TAT, APC-PCI, FM-F, F1+2, fibrinogen and D-
dimer. Increased fibrin turnover occurs on the surface of intra-luminal AAA thrombus. 
Several authors have reported a positive correlation between the extent of haemostatic 
derangement and AAA size and thrombus load. 14 85 Thus the pro-thrombotic diathesis 
witnessed in this patient population may be secondary to continuous intra-luminal thrombus 
remodelling.  
Open surgical repair causes significant haemostatic derangement in the peri-operative period 
with increased thrombin generation and activity, and increased fibrin turnover. By 3-months 
post-repair, the pro-thrombotic diathesis is similar to if not improved compared to the pre-
operative state. However, open surgical repair does not tend to complete resolution of the pre-
operative haemostatic derangement. Plasma levels of TAT and D-dimer remain elevated after 
surgery compared to healthy controls suggestive that the surgical prosthesis may be capable 
of inducing a prothrombotic derangement. Other factors that may contribute to these ongoing 
haemostatic derangements include atherosclerotic disease affecting other vascular beds with a 
number of studies reporting a positive correlation between the extent of atherosclerotic vessel 
disease and a pro-thrombotic state. 96 97 98  Red blood cell concentrates have been shown to 
have high levels of cytokines including IL-1, IL-6, and TNF which are potent coagulation 
stimulators and thus the volume of blood transfusion may contribute to the peri-operative 
coagulation derangement witnessed after aneurysm repair. 66 99 Increasing age has also been 
reported to influence biomarkers of coagulation and fibrinolysis. 100 101 
Only one study has studied the effect EVAR on coagulation/fibrinolysis in the peri-operative 
period. The small patient numbers and lack statistical power did not allow any firm 
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conclusions to be drawn from this study. However, the majority of patients demonstrated 
increased fibrin turnover with elevated levels of circulating D-dimer in the peri-operative 
phase. This may occur due to aneurysm sac exclusion with sac thrombosis resulting in 
increased coagulation and fibrinolysis activation, and platelet consumption; contrast media 
induced endothelial cell injury and platelet activation; or endothelial damage due to the 
passage of guide-wires and catheters as has been demonstrated after coronary and peripheral 
angioplasty. 53 54 102 103 104  
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3.6 SUMMARY 
AAA is associated with a pro-thrombotic diathesis proportional to the volume of intra-luminal 
thrombus. The pro-coagulant state is exaggerated in the immediate peri-operative period 
following open repair but is attenuated at medium-term follow-up although not normalised. 
These changes may account for the high level of thrombotic complications observed in this 
cohort of patients. There are currently no robust studies investigating the effect of EVAR on 
the underlying pro-thrombotic diathesis evident in AAA patients.   
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CHAPTER 4 
 
THE SHORT TERM EFFECTS OF ENDOVASCULAR ANEURYSM REPAIR (EVAR) ON 
COAGULATION AND CARDIOVASCULAR MORBIDITY AND MORTALITY IN PATIENTS 
WITH INFRA-RENAL ABDOMINAL AORTIC ANEURYSMS 
 
METHODOLOGY 
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4.1 INTRODUCTION 
This chapter describes the methodology involved in the investigation of the hypotheses 
described in chapter 1. The premise for this study is that the AAA intra-luminal thrombus 
load causes a pro-thrombotic diathesis that is attenuated upon exclusion of the aneurysm 
through endovascular stent-graft repair (EVAR).  
 
4.2 ETHICAL APPROVAL 
Ethical approval was granted by Birmingham East, North and Solihull Research Ethics 
Committee and South Birmingham Research Ethics Committee for all aspects of work 
contained within this thesis (reference: 06/Q2703/44). The study was named Coagulation, 
Endoleak and Myocardial Injury after EVAR (CEMIE) study. 
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4.3 EXPERIMENTAL DESIGN 
4.3.1 Study Design 
This is a prospective, non-randomized, multi-center study designed to investigate the short-
term haemostatic derangement in patients with abdominal aortic aneurysms undergoing 
elective EVAR. AAA–for this protocol- is defined as an asymptomatic infra-renal aortic 
aneurysm with a maximum anterior-posterior diameter measuring >5.5cm on ultrasonography 
or computed tomographic angiography (CTA).  
 
4.3.2 Patient recruitment 
Initially all patients presenting to the Vascular Surgery Units of the Heart of England NHS 
Foundation Trust and University Hospital Birmingham NHS Trust between April 2006 and 
October 2007 and undergoing EVAR were considered for inclusion in the study. However, 
due to a freezer malfunction the majority of samples/results collected from this patient cohort 
were lost or invalidated. (See appendix 2) As a result a second cohort of patients using the 
same methods and protocols for enrolment was recruited between January 2008 and 
December 2009. Thus this thesis presents two equal cohorts of patients as separate datasets: 
cohort one (April 2006- October 2007) and cohort two (January 2008- December 2009).  
Patients were primarily identified through a) liaising with lead clinicians in their respective 
vascular surgery departments and radiology departments, b) attendance at weekly vascular 
multidisciplinary team meetings, and c) attendance at outpatient clinics in the aforementioned 
hospitals.  
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Following identification of a suitable study patient (see inclusion and exclusion criteria 
below) the patient was interviewed by the lead investigator (RSM Davies) and provided with 
a comprehensive CEMIE study information leaflet. (See appendix 3) The patient was then 
allowed at least 24 hours to decide whether or not they wished to participate in the study. 
Those patients willing to participate underwent a subsequent written fully informed consent 
process with a concomitant study participation notice forwarded to the patients’ general 
practitioner. (See appendices 4 & 5) 
 
4.3.3 Patient Inclusion/Exclusion Criteria 
a) Inclusion  
All patients met the following criteria: 
1.  Males and females 50-90 years of age inclusive 
2.  Asymptomatic AAA 
3. Radiological (USS/CTA) diagnosis of an infra-renal AAA > 5.5cm 
4.  Suitable for EVAR 
5.  Smoking status stable for ! 3 months  
6.  Patient was committed and able to follow the protocol requirements as evidenced by 
written informed consent 
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b) Exclusion 
Patients were excluded if they met any of the following criteria: 
1. A non-cardiac endovascular intervention procedure other than a diagnostic 
percutaneous trans-femoral/-brachial digital subtraction angiography within the 
previous 3 months. 
2. Patients with concomitant thoracic or suprarenal aortic aneurysm or dissection 
3. Patients with significant lower limb peripheral vascular disease (Fontaine 
Classification IIb-IV) 
3. Presence of the following conditions that could confound coagulation studies: 
• History of malignancy and/or chemotherapy within the last 5 years 
• Coagulation disorders: 
! Hereditary coagulopathy e.g. Haemophilia, von Willebrand disease 
! Acquired e.g. liver disease, malabsorption syndromes 
• Thrombocytopenia e.g. bone marrow failure, idiopathic thrombocytopenic purpura 
(ITP), hypersplenism 
• Kidney Disease Outcomes Quality Initiative (KDOQI) Stage 3-5 chronic renal 
failure  
• History of deep venous thrombosis and/or venous ulceration within last 3 months 
• Evidence of sepsis or systemic inflammatory response syndrome 
• Patients with immuno-compromised conditions, organ transplant recipients, or 
those being treated with immunosuppressive pharmacotherapy  
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4.  Patients who have undergone previous surgery within the last 6 months 
5. Patients who have undergone coronary artery angiography/stent insertion within the 
last 3 months 
6. Patients who have been on treatment dose anti-coagulation pharmacotherapy within 
the last 6 months e.g. Heparin, low molecular weight heparin (LMWH), warfarin 
7. Patients with known blood borne infections e.g. Hepatitis B virus (HBV), Human 
immunodeficiency virus (HIV)  
8. Patients who have undergone a blood transfusion within the last month 
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4.3.4 Data collection 
The following patient clinico-pathological data were collected prospectively and stored in an 
encrypted database: patient age and sex; co-morbidities and medications; pre-operative 
imaging investigations; procedural details; post-operative data including imaging 
investigations, re-interventions, complications and mortality. Specifically cardiovascular 
morbidity and mortality at each study time point was recorded and all patients underwent 
ECG pre-operatively and at 24-hours post-operatively.  
 
Blood Sample Collection 
All patients had a resting venous blood sample drawn from an antecubital fossa vein without 
tourniquet at the following time points for haemostatic assays: pre-procedure, 24-hours post-
procedure, and 1-month post-procedure. Blood for the assay of myocardial injury was drawn 
pre-procedure, and 24 hours post-procedure. Post-procedure is defined as the time following 
the successful completion of EVAR.  
Blood was drawn into a standard syringe utilising a 21g hypodermic needle and then 
immediately transferred to specific tubes; a 2.7 ml sample was collected into EDTA 
anticoagulant (1.6mg/ml), a 3ml sample into sodium citrate anticoagulant (0.106 mol/l), a 9ml 
sample into a tube containing Z-serum clot activator. Samples were placed immediately on ice 
and transferred to the laboratory within 30 minutes of collection. Plasma was separated by 
centrifugation at 3,000 revolutions per minute for 30 minutes at a temperature of 4o C 
(equivalent to 1400g). Plasma and serum were separated utilising a standard 1 ml graduated 
pasteur pipette and stored in cryogenic vials at - 80 C for subsequent batch analysis.  
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4.3.5 Assay Methodology 
a) Markers of Haemostasis  
Commercially available assays were used to measure circulating levels of Thrombin-
antithrombin III-complex (TAT), Plasminogen activator inhibitor 1  (PAI-1) antigen, tissue 
plasminogen activator (t-PA) activity and soluble P-selectin (sP-Selectin).  
 
 
Figure 4.3.1: Triturus! (Grifols) fully automated enzyme immunoassay analyser 
All assays for biomarkers of coagulation, fibrinolysis and platelet activity were batch 
analysed utilising an open system Triturus! (Grifols) fully automated enzyme immunoassay 
analyser. (See figure 4.3.1) The following plasma circulating biomarkers were analysed at the 
aforementioned time points: 
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1) Marker of Coagulation 
Name: Thrombin-antithrombin III (TAT) Complex  
Biomarker of:  Thrombin generation 
Information: Thrombin plays an intricate part in coagulation initiation and platelet activation. 
Prothrombinase complex (Va-Xa) in the presence of Ca2+ acts as a catalyst converting 
prothrombin (II) into Thrombin (IIa). Thrombin released through this enzymatic process is 
inactivated by antithrombin III to form a Thrombin-antithrombin III-complex (TAT). 82 Thus 
circulating plasma levels of TAT reflect thrombin generation. 
Test Kit: AssayMax Human Thrombin-antithrombin (TAT) Complexes ELISA Kit 
Company: Assaypro! 
Principal of assay: This assay employs a quantitative sandwich enzyme immunoassay 
technique utilising an immobilised monoclonal antibody (AB) specific for antithrombin and a 
polyclonal AB -with a covalently attached biotin tag (biotinylated) - specific for thrombin. 
TAT complexes are sandwiched by the immobilized AB and biotinylated polyclonal AB that 
is recognized by an enzyme-bound streptavidin (streptavidin-peroxidase). Unbound material 
is then washed away and a peroxidase enzyme substrate catalyst is added to generate a 
coloured product whose intensity is measured.  
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2) Markers of Fibrinolysis 
Name: Plasminogen Activator Inhibitor Type-1 (PAI-1) antigen  
Biomarker of:  Fibrinolysis 
Information: PAI-1 is released from the vascular endothelium in the presence of thrombin 
and is the principal inhibitor of tissue plasminogen activator (t-PA). Through its ability to 
inhibit the activators of plasminogen, PAI-1 acts to maintain balance between clot formation 
and lysis and thus is a primary regulator of fibrinolysis. 
Test Kit: Spectrolyse !PAI-1 
Company: American Diagnostica Inc. ! 
Healthy Range: 7-43 ng/ml 
Principal of assay: This is a two-stage, indirect chromogenic assay based upon the work by 
Chmielewska and Eriksson. 105 106 The first stage consists of adding a known amount of t-PA 
(40 IU/ml) to the plasma allowing reaction with PAI-1. The second stage involves calculating 
the residual t-PA activity. This is achieved through the addition of human glu-plasminogen, 
poly-D-lysine and a chromogenic substrate for plasmin. The residual t-PA activity catalyses 
the conversion of plasminogen to plasmin stimulated by poly-D-lysine. The conversion of 
plasminogen to plasmin hydrolyses the chromogenic substrate causing a colour reaction that 
is proportional to PAI-1 content.  
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Name: Tissue plasminogen activator (t-PA) activity  
Biomarker of:  Fibrinolysis 
Information: t-PA is a 70,000 Dalton glycoprotein released from the vascular endothelium in 
response to thrombin generation. It is highly fibrin specific and when bound efficiently 
cleaves Glu-plasminogen to form plasmin and, therefore, serves as the major activator of 
fibrinolysis. The majority of circulating t-PA is complexed to PAI-1 and thus inactive.  
Therefore the active, non-complexed t-PA reflects true t-PA activity in the calculation.  
Test Kit: t-PA actibind ELISA kit 
Company: Technoclone. ! 
Healthy Range: 0 U/ml 
Principal of assay:  An AB that does not interfere with t-PA functional activity is coated onto 
a microtitre plate and used to bind t-PA contained in the test plasma sample to the plate 
surface. Following an incubation period, non-bound plasma components are washed away. 
Active non-complexed t-PA is photometrically quantified through the addition and incubation 
of an activity substrate solution containing Glu-plasminogen, cyanogen bromide fragments of 
fibrinogen and a chromogenic plasmin. The AB bound t-PA activates Glu-plasminogen to 
yield plasmin that interacts with the chromogenic plasmin substrate to release a coloured 
product. The concentration of the coloured product is proportional to the amount of non-
complexed, active t-PA in the test sample. 
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3) Marker of Platelet Function 
Name: Soluble P-Selectin (sP-selectin) 
Biomarker of:  Platelet activation 
Information: Plasma sP-selectin is an adhesion molecule predominantly found in "-granules 
of unstimulated platelets. Upon platelet activation, sP-selectin is expressed on the platelet 
surface and subsequently shed by cleavage over a short period of time. 107 108   Circulating 
levels of sP-selectin are not influenced by different anticoagulants, although levels are 
influenced by anti-platelet agents. 109 This, in combination with its ability to resist ex-vivo 
activation enables it to act as a more reliable marker of in-vivo platelet activation than 
alternative methods in patients affected by thrombotic conditions, including light 
transmittance aggregometry.  
Test Kit: Human sP-selectin ELISA 
Company: Immuno-Biological Laboratories, Inc ! 
Healthy Range: 92-212 ng/ml 
Principal of assay: This is a chromogenic assay utilising an AB sandwich immunoassay 
technique. Anti-human sP-selectin AB is immobilised onto microwells. The plasma sample is 
then added with the sP-selectin binding to the immobilised antibodies. Horseradish peroxidase 
(HRP) conjugated anti-human sP-selectin AB is then added sandwiching the bound sP-
selectin. Unbound HRP-conjugated anti-human sP-selectin is then removed and tetramethyl-
benzidine is added that reacts with HRP to form a coloured product proportional to the sP-
selectin levels present in the sample. 
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b) Marker of Myocardial injury 
Name: Cardiac troponin T (cTnT) 
Biomarker of:  Micro-myocardial infarction 
Information: Troponins are normal regulatory muscle proteins involved in the calcium 
regulated actin-myosin interactions. Three sub-types exist (T, I and C) of which Troponin T 
binds to tropomyosin attaching the troponin complex to the thin filament. 110 Troponin T 
exists as a distinct cardiac structural protein subtype (cTnT) that is released following cardiac 
muscle cell necrosis; numerous studies have demonstrated cTnT to be a highly sensitive and 
specific biomarker for micro-myocardial injury.  110 111 112 Our research group has previously 
reported that over a third of patients undergoing surgery for critical lower limb ischaemia 
sustain peri-operative micro-myocardial injury as evidenced by elevated plasma cardiac 
troponin levels. 113 Furthermore, none of these patients demonstrated any clinical evidence of 
cardiac injury or had evidence of myocardial ischaemia on ECG. cTnT is detected 3-6 hours 
after myocardial damage and reaches peak level at 12-48 hours. 
Test Kit: Cardiac troponin T enzyme immunoassay kit using the ES300 fully automated 
multichannel immuno-assay analyzer  
Company: Boehringer Mannheim  
Lower limit of detection: < 0.01 ng/ml 
Principal of assay: This test employs a standard sandwich immunoassay technique with 
streavidin-coated tubes and two monoclonal antibodies; one AB acts as the capture AB and 
binds to the streavidin-coated test tube, the second AB act as the signal AB and is labelled 
with horseradish peroxidase.  
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4.3.6 Assessment of thrombus load 
All computed tomographic aortograms (CTA) were performed according to a standard 
acquisition protocol using an Aquilion system (Toshiba). Images were uploaded to a Vitrea 
Fx (Vital Images) workstation for post-processing thrombus load calculation. The Vitrea Fx 
workstation has a semi-automated thrombus load estimation function that estimates total 
aneurysm, lumen and thrombus volumes through a process of interpolation. The start and 
endpoints were standardised to the aorta immediately distal to the lowest renal artery and the 
aortic bifurcation, respectively. (See figures 4.3.2) If the software incorrectly identified 
thrombus as lumen and vice versa, thrombus/lumen contours were manually corrected prior to 
thrombus calculation. (4.3.3) Thrombus volume is measured in cubic centimetres (CC). 
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Figure 4.3.2: Snapshot from Vitrea Fx demonstrating 3D thrombus mapping (blue arrow) and 
curvilinear projection with thrombus outlined (white arrow). 
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Figure 4.3.3: Manual remapping of lumen (white line) and thrombus (green line) contours 
using Vitrea Fx workstation.
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4.4 POWER CALCULATION AND STATISTICAL ANALYSIS 
Statistical advice was provided by Mr. Peter Nightingale (Statistician, University Hospital 
Birmingham). A priori power analysis was performed based upon previously published data 
by our research group utilising techniques described by Gottfried E Noether. A minimum 
sample size of 17 patients was calculated as being required to demonstrate a similar degree of 
haemostatic improvement following EVAR as open surgical repair with a power of 80% ("-
error =0.8) and a significance of <0.05 ("-error=0.05). 114 Based on this calculation, in 
combination with an expected drop out rate of 30% (based on our units experience in running 
research studies in similar patient populations), we estimated a minimum cohort recruitment 
of 25 patients was required.  
All analyses were carried out using StatsDirect version 2.7.2 (StatsDirect Ltd, Cheshire, UK). 
Although data sets were expected to show non-Gaussian/normal distribution, all data were 
assessed for Gaussian/normal distribution utilising the Shapiro-Wilk W test; p-value <0.05 for 
W rejects the assumption of normality. 115  
Differences between patient characteristics were assessed using Fisher’s exact test for 
categorical variables and Mann-Whitney test for continuous variables. The effect of surgical 
treatment was analysed with Wilcoxon signed-ranked test. Correlation analyses were 
performed using the Spearman rank test. Where levels of biomarkers were below the limit of 
detection of the assay, the minimum detection concentration was assigned to that sample and 
statistical analysis performed using this definition. Data are presented as median (inter-
quartile range) unless stated otherwise. A probability value of less than 0.05 was considered 
statistically significant.  
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CHAPTER 5 
 
PRE-OPERATIVE MARKERS OF COAGULATION AND FIBRINOLYSIS IN PATIENTS WITH 
ASYMPTOMATIC INFRA-RENAL ABDOMINAL AORTIC ANEURYSM UNDERGOING 
ENDOVASCULAR ANEURYSM REPAIR 
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“Blood alone moves the wheels of history.” 
Martin Luther King 
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5.1 INTRODUCTION 
Abdominal aortic aneurysms (AAA) represent a chronic inflammatory pathology and is 
usually characterised by the presence of biologically active mural thrombus directly 
proportional to the maximum AAA diameter. 55 This mural thrombus is thought to cause 
systemic haemostatic derangement characterised by increased thrombin production and 
reduced fibrinolysis. 29 The extent of this prothrombotic diathesis is reported to correlate with 
the aneurysm sac thrombus volume. 14 70 85 At the time of starting this thesis only one study 
had investigated the effect of infra-renal AAA on plasma levels of sP-selectin, a biomarker of 
platelet activity and no study has attempted to correlate plasma sP-selectin levels with 
aneurysm sac thrombus volume. 67 
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5.2 AIMS 
The aims of this study are to 1) report the effect of the presence of an infra-renal AAA on the 
circulating plasma levels of novel biomarkers of coagulation, fibrinolysis and platelet activity, 
and 2) analyse whether any haemostatic derangement including platelet activation is related to 
AAA diameter or sac thrombus volume. 
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5.3 METHODS 
Patients presenting to the Vascular Surgery Units of the Heart of England NHS Foundation 
Trust and University Hospital Birmingham NHS Trust between April 2006 and October 2007 
(cohort 1) and January 2008 and December 2009 (cohort 2) with an infra-renal AAA 
measuring >5.5 cm in maximum diameter and due to undergo endovascular AAA repair were 
assessed for study inclusion suitability. (See chapter 4.3.3) 
 
Blood sample collection 
A resting venous blood sample was drawn from an antecubital fossa vein 24 hours prior to 
EVAR. The samples were placed immediately on ice and centrifuged within 30 minutes of 
collection at 3,000 revolutions per minute for 30 minutes at a temperature of 4o C (equivalent 
to 1400g). Plasma was separated and stored at - 80 C for later batch analysis. 
 
Markers of Thrombin generation, Fibrinolysis and Platelet activity 
Plasma thrombin antithrombin III-complex (TAT) (healthy range, <4.2 µg/L) was assayed as 
a marker of thrombin generation. Plasma plasminogen activator inhibitor 1 (PAI-1) (healthy 
range, 7-43 ng/ml) and tissue plasminogen activator (t-PA) activity (healthy range, 0 U/ml) 
were assayed as markers of fibrinolysis. Soluble P-selectin (sP-selectin) (healthy range, 92-
212 ng/ml) was assayed as a marker of platelet activity. The assay’s manufacturer determined 
the healthy range for each haemostatic marker. (For further details of these commercially 
available assays please see chapter 4.3.5) 
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Assessment of thrombus load 
AAA thrombus volume, measured in cubic centimetres (CC), was calculated utilising the 
Vitrea Fx post-processing workstation. (See chapter 4.3.6)  
 
Statistics 
Differences between patient characteristics were assessed using Fisher’s exact test for 
categorical variables and Mann-Whitney test for continuous variables. Correlation analyses 
were performed using the Spearman rank test. A probability value of less than .05 was 
regarded as statistically significant. Data are presented as median (inter-quartile range). All 
analyses were carried out using StatsDirect version 2.7.2 (StatsDirect Ltd, Cheshire, UK).  
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5.4 RESULTS 
Patient Cohort 1 
30 patients (28 men, 2 women of median (IQR) age 77.5 (72-82) years) who underwent 
elective EVAR for infra-renal AAA were studied.  Patient co-morbidities are shown in table 
5.4.1. The median (IQR) pre-operative plasma levels of PAI-1 were significantly higher than 
the normal range: 51 (12.7-51) ng/ml vs. 7-43 ng/ml; p=0.05. There was no correlation 
between pre-operative anti-platelet (p = 0.71) or statin (p = 0.59) pharmacotherapy and PAI-1 
levels. 
Median (IQR) maximum aneurysm diameter was 62.5 (59-69) mms. Median (IQR) total 
aneurysm volume and aneurysm lumen volume were 210 (164-235) cc and 101 (77-125) cc. 
Median (IQR) aneurysm sac thrombus volume was 112 (95-148) cc. There was no correlation 
between aneurysm thrombus volume and maximum aneurysm diameter: r = -0.03, p = 0.89. 
There was no correlation between aneurysm thrombus volume and PAI-1 plasma levels: r = 
0.211, p = 0.41. 
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Table 5.4.1: Patient pre-operative co-morbidities and anti-platelet/statin status. 
Patient cohort 
 
1 (n = 30) 2 (n = 30) 
p-value 
Co-morbidities 
Renal failure (CKD Stage = <3) 6 4 0.51 
Diabetes 7 4 0.34 
Hypercholesterolaemia 7 2 0.09 
Ischaemic Heart Disease 10 10 >0.99 
Smoker 5 1 0.11 
Peripheral vascular disease     
(fontaine = <IIb) 11 1 0.0013 
Medication 
Antiplatelet 16 16 >0.99 
Aspirin 16 14 0.62 
Clopidogrel 0 1 0.5 
Dual therapy 0 1 0.5 
Statin 19 16 0.45 
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Patient Cohort 2 
30 patients (29 men, 1 women of median (IQR) age 75 (71-82) years) who underwent elective 
EVAR for infra-renal AAA were prospectively studied. The pre-operative plasma levels of 
PAI-1 (median (IQR) = 20.9 (8.4-50.7) ng/ml) and t-PA activity (median (IQR) = 0 (0-0) 
U/ml) were within the normal values.  
The pre-operative plasma levels of sP-selectin were significantly lower than the normal range: 
median (IQR) = 80.5 (68-128) ng/ml), p = <0.0001. The pre-operative use of a statin (median 
(IQR); 72 (66-81) vs. 84 (80-117) ng/ml, p = 0.0165) resulted in lower plasma sP-selectin 
levels. The pre-operative use of an anti-platelet (median (IQR); 73 (66-81) ng/ml vs. 84 (76-
99) ng/ml, p = 0.076) tended to result in lower sP-selectin levels.  
 
Table 5.4.2: Pre-operative values of markers of haemostasis. The arrows indicate 
comparisons to normal reference ranges. 
 
 
Pre-operative Values (median (IQR) 
Assay Normal Range 
Cohort 1 Cohort 2 
PAI-1 7-43 ng/ml 51 (12.7-51) # 20.9 (8.4-50.7) 
t-PA 0 U/ml NA 0 (0-0) 
sP-Selectin 92-212 ng/ml NA 80.5 (68-128) $ 
TAT <4.2 µg/L NA 7.15 (4.7-31.3) # 
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The pre-operative plasma levels of TAT were significantly higher than the normal reference 
range: median (IQR) = 7.15 (4.7-31.3) µg/L, P = <0.001.  There was no correlation between 
pre-operative anti-platelet (p = 0.13) or statin (p = 0.21) pharmacotherapy and TAT levels. 
(See table 5.4.2) 
Median (IQR) maximum aneurysm diameter was 66.5 (57.3-70.3) mms. Median (IQR) total 
aneurysm volume and aneurysm lumen volume were 188 (147-247) cc and 80 (54.3-107) cc. 
Median (IQR) aneurysm sac thrombus volume was 97.6 (63-127) cc. There was no 
correlation between aneurysm thrombus volume and maximum aneurysm diameter: r = 0.45, 
p = 0.15. There was no correlation between aneurysm thrombus volume and PAI-1 (r = -0.25, 
p = 0.47), sP-Selectin (r = 0.26, p = 0.43) or TAT plasma levels (r = -0.21, p = 0.54). 
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5.5 DISCUSSION 
Several prospective studies report the effects of AAA on a variety of different biomarkers of 
coagulation and fibrinolysis.  
To date only thirteen studies in the English language literature report the association between 
AAA and fibrinolysis. 14 65 69 71 70 72 73 77 78 79 116 117 118   (See tables 3.4.1 & 5.5.1) Nine 
studies report often-contradictory effects of AAA on levels of PAI-1 and/or t-PA antigen. 65 29 
71 72 77 79 118 116 117 The majority of studies report no difference in circulating t-PA antigen 
levels in patients with AAA compared to control populations. The one exception is 
Wanhainen et al who report elevated levels of t-PA antigen in patients with screen detected 
AAA suggestive of increased fibrinolysis in this cohort of patients. 117 Sofi et al report the 
largest series analysing the effects of AAA on PAI-1 levels and describes a significant 
elevation in those affected with AAA compared to a control population. The majority of our 
study’s patients have either normal or slightly increased levels of PAI-1 when compared to 
the normal reference range. Only three studies have analysed both t-PA antigen and PAI-1 
levels and all three studies report no significant difference compared to their control 
populations. 77 116 118 We analysed t-PA activity levels as a true reflection of systemic 
fibrinolysis and found comparable results in that levels were analogous to the normal range. 
Thus despite PAI-1 levels being elevated in some patients overall systemic fibrinolysis was 
normal. 
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Table 5.5.1: Latest studies investigating the association between AAA and levels of fibrinogen and biomarkers of fibrinolysis. and 
thrombin generation (* symptomatic unruptured AAA, ** manufacturer’s range, *** t-PA activity)  
Coagulation, Endoleak and Myocardial Injury after EVAR     (CEMIE Study) 
 85 
 
 
In our study patients with AAA demonstrated increased thrombin generation as evidenced by 
elevated levels of TAT. Similar findings have been reported in five of seven English language 
studies. 14 29 70 71 77 78 116 118 (See table 3.4.2 & 5.5.1) The largest study reported elevated 
levels of TAT and F1+2 on both univariate and multivariate analysis in men with small AAA: 
median (range) maximum diameter 41mm (30-55 mm). 118  In our patient cohort TAT levels 
were elevated independent of anti-platelet or statin pharmacotherapy. 
To date only one study has reported on the effects of AAA on platelet activation through the 
measurement of plasma sP-selectin. 67 P-selectin is an adhesion molecule and is expressed on 
the cell surface upon activation; plasma sP-selectin derives predominantly from platelets and 
is an accurate marker of in vivo platelet activation. 119 Blann et al reported elevated levels of 
sP-selectin in 21 patients with uncomplicated AAA implying increased platelet activation. 
The current study appears to contradict this finding in that patients with AAA had reduced 
plasma sP-selectin levels and thus depressed platelet activity. This may reflect differences in 
the proportion of patients with hypercholesterolaemia and/or treated with a statin; the majority 
of patient cohort reported by Blann et al demonstrated cholesterol levels in excess of 5.8 
mmol/l.  Patients with hypercholesteraemia have increased platelet cell-membrane cholesterol 
concentrations which results in a heightened sensitivity to platelet-aggregation inducing 
agents with increased plasma levels of P-selectin and other platelet derived micro-particles 
reported. 120  Statins inhibit platelet activation and aggregation through both cholesterol 
dependent and cholesterol independent pathways. 121 By reducing plasma cholesterol 
concentration statins disrupt platelet cell membrane phospholipid and attenuates ADP-
induced platelet aggregation. Statins have also been reported to inhibit platelet activation 
through interactions with the RhoA-Rho kinase pathway. 122 We found a direct correlation 
between statin pharmacotherapy and platelet activation.  
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To date six studies have investigated the effects of AAA thrombus volume/maximum 
thickness on haemostasis, often with contradictory results. 14 69 70 123 124 125 (See table 5.5.2) 
Both Yamazumi et al and Aho et al reported a correlation between AAA total thrombus 
volume/maximum thrombus thickness and changes in biomarkers of systemic fibrinolysis. 
However, only Yamazumi et al reported a positive correlation between maximum thickness of 
intraluminal AAA thrombus and heightened thrombin generation. 14  
In direct contradiction, Kolbel et al, using APC-PCI as a marker of thrombin generation, 
reported no correlation between thrombus volume or thrombus intra-luminal surface area and 
the underlying pro-coagulant state. 124 The present study failed to show a correlation between 
systemic thrombin generation and total aneurysm thrombus volume. These discrepancies may 
reflect differing methods of thrombus volume measurement. We utilised a semi-automated 
interpolation method using a Vitrea Fx post-processing workstation. This compares to Kolbel 
et al who estimated thrombus volume using the formula for measuring the volume of a 
cylindrical tube, and Yamazumi who utilised 2D computed tomography. Thus we believe our 
methodology to better reflect the true thrombus volume as it allows for varying vessel 
morphologies in the calculation. 
In conclusion, the present study confirms that patients with AAA demonstrate haemostatic 
derangement, but the extent of the haemostatic derangement does not correlate with the 
volume of intra-luminal aneurysm thrombus.  
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CHAPTER 6 
 
THE SHORT TERM EFFECTS OF ENDOVASCULAR ANEURYSM REPAIR ON MARKERS 
OF COAGULATION, FIBRINOLYSIS AND PLATELET ACTIVITY IN PATIENTS WITH 
ASYMPTOMATIC INFRA-RENAL ABDOMINAL AORTIC ANEURYSMS 
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6.1 INTRODUCTION 
Elective EVAR for asymptomatic AAA is associated with a 60% reduction in peri-operative 
mortality when compared to open surgical repair in the fit and anatomically suitable patient. 7 
126 However, exponents of EVAR argue that these initial short-term benefits are offset by the 
long-term propensity for stent-related complications, in particular endoleak. 13 Endoleak is a 
complication unique to EVAR and results in aneurysm sac reperfusion. The EVAR-1 trial 
reported one quarter of EVARs were complicated by endoleak, with one third requiring a 
secondary procedure to maintain complete aneurysm exclusion within 3 years of the index 
procedure. 7 Thus it is necessary for all patents to be entered into a stent-graft surveillance 
program to identify stent-graft failure prior to aneurysm sac rupture. Despite imaging 
protocols undergoing considerable evolution this need for long-term follow-up poses a 
significant socio-economic burden on the treating institution. 11 
Major surgery is known to produce a pro-thrombotic derangement with elevated plasma 
biomarkers of thrombosis reported in the post-operative period. 43 44 46 47 48 49 127 Patients 
undergoing major lower limb arterial reconstructive surgery exhibit defective endogenous 
fibrinolytic activity; increased levels of PAI-1 and t-PA antigen that return to pre-operative 
levels by one week post-procedure. 92 93 94  
Open surgical repair of an infra-renal AAA causes significant haemostatic derangement in the 
peri-operative period with increased thrombin generation and activity, and increased fibrin 
turnover reported during the first week. This pro-coagulant state would appear to attenuate 
thereafter such that by 3-months post-repair the pro-thrombotic diathesis is similar to, if not 
improved, compared to the pre-operative haemostatic state. However, open surgical repair 
does not lead to resolution of the pre-operative derangement.  
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 Careful review of the literature has revealed no studies investigating the effect of EVAR on 
biomarkers of coagulation, fibrinolysis and platelet activity. We hypothesised that 1) similar 
changes to systemic coagulation, fibrinolysis, and platelet activity would occur following 
EVAR and 2) failure to exclude the aneurysm sac from the systemic circulation, in the form 
of an endoleak, would result in the re-establishment of the heightened pre-operative 
thrombotic state.  
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6.2 AIMS 
The aim of this chapter is to 1) investigate peri-operative changes in plasma levels of 
biomarkers of coagulation, fibrinolysis and platelet activity following EVAR for 
asymptomatic AAA, and 2) examine the relationship between peri- and post-operative 
changes in coagulation, fibrinolysis and platelet function following the development of 
endoleak after EVAR. 
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6.3 METHODS 
Patients presenting to the Vascular Surgery Units of the Heart of England NHS Foundation 
Trust and University Hospital Birmingham NHS Trust between April 2006 and October 2007 
(cohort 1), and January 2008 and December 2009 (cohort 2) with an infra-renal AAA 
measuring > 5.5 cm in maximum diameter and due to undergo endovascular AAA repair were 
assessed for study inclusion suitability. (For inclusion and exclusion criteria see chapter 4.3.3)  
 
Blood sample collection 
A resting venous blood sample was drawn from an antecubital fossa vein 24 hours prior to, 
24-hours after and 1-month following EVAR. The samples were placed immediately on ice 
and centrifuged within 30 minutes of collection at 3,000 revolutions per minute for 30 
minutes at a temperature of 4o C (equivalent to 1400g). Plasma was separated and stored at - 
80 C for later batch analysis. 
 
Markers of Thrombin generation, fibrinolysis and Platelet activity 
Plasma thrombin antithrombin III-complex (TAT) (healthy range, <4.2 µg/L) was assayed as 
a marker of thrombin generation. Plasma plasminogen activator inhibitor 1 (PAI-1) (healthy 
range, 7-43 ng/ml) and tissue plasminogen activator (t-PA) activity (healthy range, 0 U/ml) 
were assayed as a marker of fibrinolysis. Soluble P-selectin (sP-selectin) (healthy range, 92-
212 ng/ml) was assayed as a marker of platelet activity. The assay’s manufacturer determined 
the healthy range for each haemostatic marker. (For further details of these commercially 
available assays please see chapter 4.3.5) 
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Assessment for Endoleak 
All patients underwent computed tomography angiography assessment at 24 hours and 1-
month post-EVAR to assess for endoleak. 
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Statistics 
Differences between patient characteristics were assessed using Fisher’s exact test for 
categorical variables and Mann-Whitney test for continuous variables. Wilcoxon signed-
ranked test was used to assess the effects of EVAR at different time points. Correlation 
analyses were performed using the Spearman rank test. Where levels of assays were below 
the lower limit of assay detection, this level was assigned for statistical analysis. A probability 
value of less than .05 was regarded as statistically significant. Data are presented as median 
(inter-quartile range). All analyses were carried out using StatsDirect version 2.7.2 
(StatsDirect Ltd, Cheshire, UK).  
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6.4 RESULTS 
Patient Cohort 1 
30 patients (28 men 2 women of median (IQR) age 77.5 (72-82) years) underwent EVAR. 22 
patients underwent insertion of a Zenith Endovascular stent-graft (Cook, Bloomington, 
Indiana) under loco-regional anaesthesia and 8 patients underwent insertion of a Gore 
Excluder stent-graft (W. L. Gore & Associates, Flagstaff, Arizona) under general anaesthesia. 
EVAR was successfully completed in all patients and there were no in-hospital deaths. 
 Median (IQR) levels of PAI-1 pre-operative, 24-hours post-operation and 1-month post-
operation were 51 (12.7-51) ng/ml, 43.8 (22.2-51) ng/ml and 36 (31.7-45.1) ng/ml. There was 
no significant difference in plasma levels of PAI-1 between pre-operation and 24-hours post-
operation (p = 0.23), pre-operation and 1-month post-operation (p = 0.67) or 24-hours post-
operation and 1-month post-operation (p = 0.37). (See figure 6.4.1). 
 Median (IQR) levels of PAI-1 pre-operative, 24-hours post-operation and 1-month post-
operation for patients undergoing EVAR under general anesthesia/Gore Excluder were 20.3 
(9.2-50.2) ng/ml, 45 (22.6-51) ng/ml and 33.8 (31.2-44.9) ng/ml, respectively.  Median (IQR) 
levels of PAI-1 pre-operative, 24-hours post-operation and 1-month post-operation for 
patients undergoing EVAR under loco-regional anesthesia (Zenith stent) were 51 (40.6-51) 
ng/ml, 42 (13.8-51) ng/ml and 36.9 (31.7-47.7) ng/ml, respectively. There was no significant 
difference in changes to plasma PAI-1 levels at 24-hours (p = 0.47) or 1-month (p = 0.21) 
post-operation when stratified for those EVARs using Zenith or Gore Excluder stent-grafts. 
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Figure 6.4.1: Comparison of plasma levels of PAI-1at pre-operation, 24 hours post-operation 
and 1-month post-operation. 
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Effect of Endoleak 
Seven patients demonstrated evidence of an endoleak at 1-month follow-up post-EVAR: type-
2 = 6, type-1 = 1. Median (IQR) difference in plasma levels of PAI-1 between baseline and 1-
month post-EVAR for patients with and without endoleak were -13.1 (-25-14.1) ng/ml and 
12.3 (0-17.3) and ng/ml, respectively (p = 0.043). (See figure 6.4.2) Two patients with 
endoleaks had positive differences (+14.1 ng/ml and +1.1 ng/ml) between PAI-1 levels at 1-
month and baseline  
 
 
 
Figure 6.4.2: Median (IQR) differences of PA-1 levels between baseline and 1-month post-
EVAR in patients with or without endoleak.
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Patient Cohort 2 
30 patients (29 men and 1 women of median (IQR) age 75 (71-82) years) underwent EVAR. 
All EVARs were performed using a Zenith Endovascular stent-graft (Cook) and were 
performed under loco-regional anaesthesia. There were no in-hospital deaths and EVAR was 
successfully completed in all patients. Changes in coagulation, fibrinolysis and platelet 
activity parameters are illustrated in table 6.4.1 
 
 
Table 6.4.1: Effect of EVAR on coagulation, fibrinolysis and platelet activity parameters. 
 
POST-OPERATIVE VALUES 
BIOMARKERS NORMAL 
RANGE 
PRE-OPERATIVE 
VALUES 
24 HOURS 1-MONTH 
PAI-1(ng/ml) 7-43 ng/ml 20.9 (8.4-50.7) 30.75 (19.8-46.8) 30.25 (15.8-56.9) 
t-PA (U/ml) 0 U/ml 0 (0-0) 0 (0-0) 0 (0-0.06) 
sP-Selectin 
(ng/ml) 92-212 ng/ml 80.5 (68-128) 89.5 (73-112) 110 (89-143) 
TAT (µg /ml) <4.2 µg/L 7.15 (4.7-31.3) 21.65 (13-33.1) 8.1 (5.4-14.85) 
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We noted no significant differences between pre-operative, 24-hours post-operative and 1-
month post-operative levels of PAI-1. A significant increase in sP-selectin levels occurred 
between pre-operation and 24-hours post-operation (p = 0.003), pre-operation and 1-month 
post-operation (p = <0.0001) and 24-hours and 1-month post-operation (p = 0.0003). There 
was increased t-PA activity at 1-month post-operation compared to pre-operation (p = 0.0012) 
and 24-hours post-operation (p = 0.0012). There was a trend towards increased thrombin 
generation at 24 hours compared to pre-operation (p = 0.069) followed by a significant 
decrease at 1-month (p = <0.0001) such that thrombin generation returned to pre-operative 
levels by 1-month post-EVAR. (See figures 6.4.3 – 6.4.6). 
 
Effect of Endoleak 
No endoleaks occurred in this patient cohort at 1-month post-procedure. Combining the 
results from patient cohorts 1 and 2 median (IQR) difference in plasma levels of PAI-1 
between baseline and 1-month post-EVAR for patients with and without endoleak were -13.1 
(-25-14.1) ng/ml and 2.8 (-9.4-16) ng/ml, respectively (p = 0.079). 
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Figure 6.4.3: Comparison of plasma levels of PAI-1at pre-operation, 24 hours post-operation 
and 1-month post-operation. 
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Figure 6.4.4: Comparison of plasma levels of t-PA activity at pre-operation, 24 hours post-
operation and 1-month post-operation. 
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Figure 6.4.5: Comparison of plasma levels of sP-selectin at pre-operation, 24 hours post-
operation and 1-month post-operation. 
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Figure 6.4.6: Comparison of plasma levels of TAT at pre-operation, 24 hours post-operation 
and 1-month post-operation. 
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6.5 DISCUSSION 
Only five studies to date have examined the effects of EVAR on coagulation and fibrinolysis 
and platelet activity.  17 93 125 128 129  
(Studies reporting the effects of EVAR on coagulation, fibrinolysis and platelet levels are 
summarised in table 6.5.1) 
Aho et al investigated the impact of EVAR on haemostasis in seventeen patients with AAA. 
125 They reported a three-fold increase in TAT levels at 24 hours followed by a gradual 
decline over the ensuing week. A similar transient increase was demonstrated for prothrombin 
fragments 1 & 2 (F 1+2), a marker of factor Xa activity and thus thrombin generation. Levels 
of both TAT and F 1+2   returned to pre-operative values by 1-week post-EVAR, however 
levels remained elevated when compared to the normal ranges. The current study reports 
similar findings with intense thrombin generation occurring within 24-hours of EVAR 
followed by a return to up-regulated pre-operative levels by 1-month. Engleberger et al 
demonstrated similar effects with elevated levels of plasma markers of thrombin generation 
(TAT) and activity (fibrin monomer (FM) and fibrinopeptide A (FPA)) occurring in the peri-
operative period. 129 Maximum levels of TAT and FPA were found at the end of surgery 
whereas FM levels were at their highest at 24 hours post-EVAR. This may reflect the 
differing plasma kinetics of these markers; TAT and FPA reflect acute thrombin generation 
and activity due to their short half-life (TAT t1/2 = 15 minutes, FPA t1/2= 3-5 minutes) whereas 
FM reflects the overall coagulation process due to its much longer half –life (t1/2 > 3 hours).  
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Serino et al reported the short-term effects of EVAR on circulating D-dimer levels in nine 
patients assessed pre-operatively and day four post-operatively. 17 D-dimer levels were 
elevated in seven patients and decreased in two patients; the median level for the entire 
patient cohort did not demonstrate a statistically significant difference between baseline and 
day four post-operation; this may reflect the study’s lack of statistical power.  
Monaco et al reported a significant decrease in levels of platelets, fibrinogen, plasminogen 
and prothrombin activity in patients undergoing EVAR during the first 10 days post-
procedure. 128 This was coupled with increased D-dimer and FDP levels suggestive of a 
coagulation factor/platelet consumption coupled with systemic hyper-fibrinolysis during the 
peri-operative period in patients undergoing EVAR. By one-month post-EVAR all 
biomarkers returned to pre-operative levels with the exception of fibrinogen, which peaked at 
one-month and remained significantly elevated at six-month post-EVAR.  
To date only Aho et al have reported the effect of EVAR on systemic fibrinolysis through the 
investigation of t-PA antigen and PAI-1 antigen levels. This group reported elevated levels of 
both t-PA antigen and PAI-1 antigen during the first 24-hours post-operatively compared to 
pre-operatively, thereafter returning to baseline levels by 1-week. However, t-PA antigen and 
PAI-1 antigen levels remained within the normal reference ranges throughout. The current 
study is the first to investigate t-PA activity as a marker of fibrinolysis following EVAR. t-PA 
activity better reflects the true state of systemic fibrinolysis compared to t-PA antigen which 
reflects the level of inactive circulating t-PA/PAI complexes. Thus despite normal levels of 
PAI-1 antigen we report a proportion of patients demonstrate heightened systemic fibrinolysis 
at one month post-operation as evidenced by elevated levels of t-PA activity. This finding is 
consistent with elevated levels of D-dimer reported at 3-months by Aho et al despite PAI-I 
antigen and t-PA antigen levels returning to baseline values at 1-week post-EVAR. 125 
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Only one previous study has reported the effects of EVAR on platelet activity utilising novel 
markers of platelet activity. Aho et al reported P-selectin levels as reducing during the first 
three days post-operative and then returning to baseline levels by one-week. P-selectin levels 
measured at 3-months were elevated in the EVAR group. 125 We report elevated platelet 
activity as evidenced by increased levels of sP-selectin at both 24-hours and 1-month post-
operation. However, at both time points levels remained within normal reference ranges. 
The Perioperative Ischemia Randomized Anesthesia Trial demonstrated that patients 
undergoing lower limb revascularisation under epidural anaesthetic did not show any change 
between pre- and peri-operative PAI-1 levels and suffered fewer post-operative graft 
thromboses. 130 This was in comparison to patients operated under general anaesthesia where 
PAI-1 levels were significantly higher in the peri-operative period as was the early graft 
thrombosis rate. Other studies have shown fewer post-operative thrombotic complications in 
patients undergoing major surgery under loco-regional anaesthesia. 131 The ability of loco-
regional anaesthesia to attenuate the catecholamine and cortisol biochemical response to 
trauma may account for the reported haemostatic benefits when compared to general 
anaesthesia. However, this apparent benefit has not been uniformly reported; Parrson et al 
report elevated levels of PAI-1 in patients undergoing infra-inguinal vascular reconstruction 
under epidural anaesthesia in the first 48 hours post-operative. 132 The current study is the first 
to report the effects of differing methods of anaesthesia on haemostasis in patients undergoing 
EVAR. We found no significant differences in peri-operative plasma PAI-1 levels between 
patients undergoing EVAR under loco-regional or general anaesthesia. A number of 
confounding factors may account for this lack of difference including differing peri-operative 
analgesic regimes and type of stent-graft deployed. Furthermore the study was not powered to 
detect such differences. 
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To date, radiological imaging is required to identify endoleak and other stent related 
complications.  There has been interest in utilising changes in circulating levels of biomarkers 
as an alternative means of identifying endoleak following EVAR. Sangiorgi et al and Lorelli 
et al have both reported elevated levels of circulating metalloproteinase-3 and -9 (MMP-3 & 
MMP-9) in patients affected by AAA. 15 16 Furthermore, successful endovascular repair 
causes a decrease in MMP levels, whereas the presence of an endoleak post-EVAR appears to 
attenuate this decrease. Only one study has investigated the effects of endoleak on levels of a 
haemostatic biomarker in patients undergoing EVAR. 17 Serino et al reported patients with a 
type-1 endoleak and stable/increasing aneurysm sac diameter demonstrated heightened 
circulating D-dimer levels compared to patients with an endoleak with a decreasing aneurysm 
sac diameter. The current study suggests that patients undergoing EVAR complicated by 
endoleak demonstrate a relative increase in systemic fibrinolysis as evidenced by a reduction 
in PAI-1 plasma levels at 1-month compared to pre-operative levels. Further research is 
required in larger groups of patients. 
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Table 6.5.1: Summary of studies investigating the effects of EVAR on biomarkers of haemostasis (* manufacturer’s range)
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In conclusion, the principal finding of this study is that EVAR causes significant haemostatic 
derangement in the peri-operative period with increased platelet activity and thrombin 
generation (as evidenced by increased sP-selectin and TAT levels) demonstrated at 24-hours 
post-operation. At 1 month the amplified thrombin generation has largely resolved with TAT 
levels returning to pre-operative levels, although remaining elevated above the normal healthy 
range. Conversely, platelet activity continues to increase during the first month post-
operation. Furthermore, a proportion of patients demonstrate increased systemic fibrinolysis 
at 1-month post-EVAR as evidenced by elevated levels of t-PA activity.  
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CHAPTER 7 
 
PERI-OPERATIVE MYOCARDIAL INJURY AND HAEMOSTASIS IN PATIENTS 
UNDERGOING ENDOVASCULAR ANERUYSM REPAIR FOR ASYMPTOMATIC INFRA-
RENAL ABDOMINAL AORTIC ANEURYSM 
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7.1 INTRODUCTION 
Cardiac related complications, including myocardial ischaemic injury, are reported to occur in 
5% of patients in the peri-operative period following EVAR. 11 This may represent a 
significant under-estimation of the true rate of myocardial injury due to sub-clinical events 
remaining undiagnosed. 113 133 134 135  
To date no study has reported on the routine use of cardiac troponins as a method for 
identifying patients with sub-clinical myocardial injury following EVAR, or attempted to 
correlate cTn levels with the haemostatic derangement that can occurs as a result of EVAR.  
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7.2 AIMS 
The aim of this study is to 1) investigate the incidence of myocardial injury in patients 
undergoing EVAR through the routine measurement of peri-operative cTn, and 2) investigate 
and correlate any increase in cTn with concomitant haemostatic derangement.  
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7.3 METHODS 
All patients presenting to the Vascular Surgery Units of the Heart of England NHS 
Foundation Trust and University Hospital Birmingham NHS Trust between January 2007 and 
January 2009 with an infra-renal AAA measuring >5.5 cm in maximum diameter and due to 
undergo EVAR were assessed for study inclusion suitability. (For study inclusion and 
exclusion criteria see chapter 4.3.3)  
 
Assessment for Myocardial Injury 
Patients were assessed pre-operatively for cardiovascular disease including a full history and 
examination. Pre-operative electrocardiograms (ECG’s) were performed. Post-operative 
complications including myocardial infarction, cardiac failure, unstable angina and cardiac 
dysrhythmias were assessed for clinically. All patients underwent routine ECG at 24 hours 
and severe ischaemia was defined as ST-elevation/depression >2mm in two or more leads.  
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Blood sample collection 
A resting venous blood sample was drawn from an antecubital fossa vein 24 hours prior to 
EVAR and 24 hours post EVAR. The samples were placed immediately on ice and 
centrifuged within 30 minutes of collection at 3,000 revolutions per minute for 30 minutes at 
a temperature of 4o C (equivalent to 1400g). Plasma was separated and stored at - 80 C for 
later batch analysis. 
 
Cardiac troponin-T levels  
All patients underwent routine cardiac troponin T (cTnT) measurement 24 hours post-
procedure using an ES300 fully automated second-generation multichannel immuno-assay 
analyzer (Boehringer Mannheim). This second-generation test does not detect cross-reacting 
isoforms from skeletal muscle. The lower limit for cTnT detection using this analyzer is 
<0.01 ng/ml; cTnT values equal to or greater than 0.03 ng/ml were considered positive for 
myocardial injury. 136  
 
Markers of Thrombin generation, fibrinolysis and Platelet activity 
Plasma thrombin antithrombin III-complex (TAT) (healthy range, <4.2 µg/L) was assayed as 
a marker of thrombin generation. Plasma plasminogen activator inhibitor 1 (PAI-1) (healthy 
range, 7-43ng/ml) and tissue plasminogen activator (t-PA) activity (healthy range, 0 U/ml) 
were assayed as markers of fibrinolysis. Soluble P-selectin (sP-selectin) (healthy range, 92-
212 ng/ml) was assayed as a marker of platelet activity. The assay manufacturer determined 
the healthy range for each haemostatic marker. (For further details of these commercially 
available assays please see chapter 4.3.5) 
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Statistics 
Differences between patient characteristics were assessed using Fisher’s exact test for 
categorical variables and Mann-Whitney test for continuous variables. Correlation analyses 
were performed using the Spearman rank test to test the null hypothesis and Kendall rank 
correlation to test the strength of dependence between two variables if the null hypothesis was 
rejected. Where levels of cTnT were below the limit of detection of the assay, a value of 0.01 
ng/ml was assigned. A probability value (p-value) of less or equal to 0.05 was regarded as 
statistically significant. Data are presented as median (inter-quartile range). All analyses were 
carried out using StatsDirect version 2.7.2 (StatsDirect Ltd, Cheshire, UK).  
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7.4 RESULTS 
General 
30 patients (29 men and 1 women of median (IQR) age 75 (71-82) years) who underwent 
elective EVAR for infra-renal AAA were prospectively studied. Ten patients had ischaemic 
heart disease co-morbidity, four patients suffered with diabetes, four patients suffered with 
chronic renal failure (Stage <3), one patient was an active smoker and one patient suffered 
with peripheral vascular disease (Fontaine Classification < IIb). Sixteen patients were being 
treated with an anti-platelet agent (aspirin = 14, clopidogrel = 1, aspirin & clopidogrel = 1); 
sixteen patients were being treated with a statin.  
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Myocardial Injury 
Two patients (7%) suffered with significant cardiac complication within 24 hours of EVAR. 
One patient suffered with central chest pain and hypotension accompanied by ischaemic ECG 
changes (ST-depression) and an elevated cTnT level (0.042 ng/ml). He was successfully 
treated for acute coronary syndrome with a glyceryl trinitrate (GTN) infusion for 24 hours. 
One patient developed fast atrial fibrillation requiring rate control pharmacotherapy; cTnT at 
24 hours post-procedure was significantly elevated; cTnT = 0.178 ng/ml. Three patients 
without clinical or ECG evidence of myocardial injury had cTnT levels >0.03 ng/ml; patient 2 
cTnT = 0.04 ng/ml, patient 8 cTnT = 0.134 ng/ml, patient 25 cTnT = 0.058 ng/ml.  Six 
patients without clinical or ECG evidence of myocardial injury had cTnT levels >0.01 ng/ml; 
patient 7 cTnT = 0.023 ng/ml, patient 11 cTnT = 0.012 ng/ml, patient 18 cTnT = 0.019 ng/ml, 
patient 19 cTnT = 0.021 ng/ml, patient 27 cTnT = 0.021 ng/ml, patient 29 cTnT = 0.021 
ng/ml. (See figure 7.4.1) There was no association between pre-operative anitplatelet or statin 
usage and myocardial injury (p = NS) 
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Figure 7.4.1: Individual patient data points for cTnT. The red points represent the two 
patients with clinical/ECG signs of cardiac injury. 
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Relationship between haemostatic markers and cTnT 
Median (IQR) plasma levels of sP-selectin were 80.5 (68-86) ng/ml pre-operatively and 89.5 
(73-112) ng/ml 24 hours post-EVAR (p = 0.0028). There was no correlation between raised 
cTnT levels and pre-operative (r = -0.06, p = 0.76) or 24 hours post-EVAR (r = 0.23, p = 
0.22) levels of sP-selectin.  
Median (IQR) plasma levels of PAI-I were 20.9 (8.4-50.7) ng/ml pre-operatively and 30.75 
(19.8-46.8) ng/ml 24 hours post-EVAR (p = 0.75). There was no correlation between raised 
cTnT levels and pre-operative (r = 0.03, p = 0.87) or 24 hours post-EVAR (r = 0.12, p = 0.54) 
levels of PAI-I. Median (IQR) plasma levels of t-PA were 0 (0-0) U/ml pre-operatively and 0 
(0-0) U/ml 24 hours post-EVAR (p = 0.6875).  
Median (IQR) plasma levels of TAT were 7.15 (4.7-31.3) µg/l pre-operatively and 21.65 (13-
33.1) µg/l 24 hours post-EVAR (p = 0.069). There was no correlation between raised cTnT 
levels and pre-operative (r = 0.11, p = 0.56) levels of TAT. There was a positive correlation 
between cTnT and TAT levels at 24 hours post-EVAR (r=0.38, p = 0.039, Kendall tau B = 
0.26) (see figure 7.4.2) 
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Figure 7.4.2: Box and Whisker plot of haemostatic variables pre- and 24 hours post-EVAR. 
Spearman’s rank correlation coefficient (r) and p-value for each haemostatic variable vs. 
cTnT is shown.  
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7.5 DISCUSSION 
This is the first study to investigate the routine use of cTnT as a marker of myocardial injury 
and its association with altered peri-operative haemostasis following EVAR. The principle 
findings of the present study are a) EVAR is associated with a significant risk of myocardial 
injury [5 of 30 patients (16%)], as demonstrated by elevated levels of cTnT, and b) the pro-
thrombotic state that occurs in the peri-operative period after EVAR is associated with 
myocardial injury. 
Cardiac troponins (cTn) are highly sensitive and specific markers of myocardial necrosis. An 
elevated peri-operative cTnT is an independent predictor of peri-operative and long-term 
mortality. 30 136 137 134 Kertai el al reported peri-operative cTnT levels >0.1 ng/ml were 
independently associated with a two-fold increased risk of long-term mortality following 
successful major vascular surgery. 30 Landesberg et demonstrated that even minor elevations 
in post-operative cTnT levels was a predictor of increased mortality; cTnT levels >0.1 ng/ml 
and >0.03ng/ml independently predicted a 2.06 and 1.89 fold increase in mortality following 
major vascular surgery, respectively. 136 In our study, utilising 0.03ng/ml as the cut-off level 
for myocardial injury, 5 patients suffered peri-operative myocardial injury as opposed to 2 
patients if the conventional cut-off of 0.1 ng/ml was utilised. This is considerably higher than 
the 5% peri-operative cardiovascular morbidity reported by Drury et al in their Cochrane 
review of endovascular aneurysm repair.   
A number of studies have shown that routine cTnT surveillance in the peri-operative period 
identifies a significant number of patients with sub-clinical myocardial injury following major 
vascular surgery. 113 133 134 135 Hobbs et al reported 38% of patients undergoing surgery for 
critical limb ischaemia had evidence of peri-operative myocardial injury as evidenced by 
raised cardiac troponin levels; only one third of these cases were clinically apparent. 113 
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Haggart et al reported that more than one quarter of patients undergoing elective open surgical 
AAA repair suffer peri-operative myocardial injury. 23 However, 50% of these events 
remained sub-clinical, identified only through routine monitoring of cardiac troponins. 23 In 
our study only 2 of 5 patients with peri-operative levels of cTnT >0.03 ng/ml demonstrated 
clinical evidence of cardiac dysfunction. Thus 10% of patients with peri-operative myocardial 
injury would have gone undetected if routine surveillance with cTnT had not been 
undertaken. 
The present study demonstrates a correlation between myocardial injury and increased peri-
operative thrombin generation. Gibbs et al reported an association between the peri-operative 
hypercoagulable state following open abdominal aortic surgery and peri-operative myocardial 
infarction. 138 However, this study was limited to Q-wave infarcts whereas the majority of 
peri-operative MI are non-Q-wave. 133 In the present study there were no Q-wave infarcts, but 
the association between myocardial injury as defined by cTnT >0.03 ng/ml and a 
hypercoagulable state was maintained. This may suggest that the elevated cTnT levels, with 
the exception of the patient who developed atrial fibrillation, are secondary to a true 
thrombotic myocardial injury.  However, platelet activation and aggregation is the initial step 
in the formation of clot and the present study did not demonstrate any correlation between 
elevated cTnT and peri-operative platelet activation. The cTnT elevation witnessed in the 
peri-operative phase of the present study may represent myocardial stress from causes other 
than thrombosis. 
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In conclusion, EVAR is associated with a significant risk of peri-operative myocardial injury 
that is under-detected clinically. The resultant pro-coagulopathic state following EVAR may 
be associated with an increased risk of myocardial injury. The routine use peri-operative cTnT 
as marker of myocardial injury testing may allow for the identification of patients at increased 
risk of mortality and the judicious use of peri-operative anti-coagulantion may help prevent 
myocardial injury. 
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CHAPTER 8 
 
AREAS OF FUTURE RESEARCH 
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8.1 THE RELATIONSHIP BETWEEN MURAL THROMBUS AND HAEMOSTASIS 
The current study has not demonstrated the expected correlation between aneurysm thrombus 
volume and biomarkers of haemostasis. However, these results do not necessarily exclude the 
thrombus from being of importance in the prothrombotic state we report in patients with 
AAA. Vascular surgeons operating on AAA will note that the thrombus composition and 
density is often considerably different between patients. On occasion the thrombus can be 
removed en masse with little fracturing, whereas in other patients the thrombus is very fragile 
and semi-viscous in consistency. Microscopic examination of the mural thrombus reveals a 
highly complex network of inter-connecting canaliculi. These exponentially increase the 
surface area in direct contact with the luminal contents in a similar fashion to the villi and 
microvilli of the gastrointestinal tract. Thus, the mural thrombus is a biologically active entity 
that is not uniform in architecture, composition or density at a macro- or microscopic level. 
These differences may directly impact the level of haemostatic derangement an AAA exerts 
on the systemic circulation and may account for the conflicting studies reported in the English 
literature. (see table 3.4.4)  
To date only Kolbel et al have investigated the relationship between thrombin activation and 
thrombus luminal surface area (TLS). 85 This group reported no correlation between the APC-
PCI levels and surface area in 130 patients. The study was limited by its methodology in that 
it did not quantify the additional surface area contributed by macroscopic thrombus surface 
irregularities and microscopic canaliculi thereby grossly underestimating the TLS. In order to 
investigate this relationship comprehensively an accurate method for measuring true TLS is 
required. This is extremely difficult and is akin to measuring the surface area of grass on a 
football field. Currently, to the best of our knowledge, no non-invasive/radiographical method 
is available to measure the surface area of the thrombus with the canaliculi taken into account. 
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One potential solution is the utilisation of microscopic optical planimetry as described by 
Spring et al. 139 The technique utilises optical cross-sectional imaging in multiple planes at 
1!m intervals through a tissue sample allowing an accurate computer 3D- reconstruction. 
From this 3D- reconstruction surface area and volume can be extrapolated. In the case of 
mural thrombus the luminal surface area of a known volume of thrombus biopsied during 
open repair can be utilised to estimate the luminal surface area for the total volume of 
thrombus. Furthermore, the method of calculating thrombus volume described in Chapter 3 
could be validated by the direct measurement of thrombus volume removed at open operation.    
The current study did not investigate the differing thrombus biological qualities/variables and 
in particular the TLS. We speculate that the TLS may demonstrate correlation with markers of 
haemostasis if assessed appropriately and that further investigation is required to 
establish/refute any such relationship.  
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8.2 BIOMARKER OF ENDOLEAK 
The current study investigated the novel use of biomarkers of haemostasis as a potential 
marker of endoleak as a secondary outcome. However, the results from this secondary 
outcome are of limited clinical value due to a) the study was not powered to investigate this 
relationship, and b) the lack of endoleak occurring in the second cohort of patients.  
We report endoleak occurring in 12% of patients within one month post-procedure. This 
compares to the reported incidence of 22% in the EVAR-1 trial. 7  However, it is the clinically 
significant endoleaks, those associated with sac expansion, that we wish to identify and only 
one (2%) patient from the current study required re-intervention secondary to a type-1 
endoleak. In order for a study to be sufficiently powered to investigate a relationship between 
clinically significant endoleaks and novel markers of haemostasis we estimate a patient cohort 
of >1000 would be required. Thus, a multi-centre, multi-regional study is required to 
investigate this relationship further. 
Coagulation, Endoleak and Myocardial Injury after EVAR      (CEMIE Study) 
 127 
 
 
8.3 MYOCARDIAL INJURY AND EVAR 
Perhaps the most clinically relevant finding of the current study is patients undergoing EVAR 
are at significant risk of peri-operative myocardial injury of which significant proportions are 
clinically occult. It is established that patients with peri-operative cardiac troponin elevation 
with or without clinical evidence of myocardial injury demonstrate adverse cardiovascular 
short- and medium term-outcomes. Therefore the ability to pre-operatively identify 
individuals at increased risk of peri-operative myocardial injury may allow targeted 
optimisation to occur.  
B-type natriuretic peptide (BNP) and its pro-hormone N-terminal fragment pro-BNP (NT-pro-
BNP) have recently been investigated as a potential pre-operative predictor of peri-operative 
myocardial injury. 140 141 142 Rajagopalan et al demonstrated a pre-operative cut-off value for 
NT-pro-BNP of 308 pg/ml correctly indentified patients at heightened risk of peri-operative 
myocardial injury as identified by a cardiac troponin rise. 143 Feringa et al reported a pre-
operative NT-pro-BNP value of >533 pg/ml was independently associated and more accurate 
than pre-operative dobutamine stress echocardiography in predicting early post-operative 
adverse cardiac events. 142 To date no study has utilised NT-pro-BNP as a pre-operative risk 
stratification method for peri-operative cardiac injury in patients undergoing EVAR. 
The best means of pre-operative cardiac optimisation in patients at risk for peri-operative 
adverse cardiac events remains unknown. A number of studies have investigated the use of 
peri-operative !-blockers as a cardio-protective pharmacotherapy in patients undergoing non-
cardiac surgery. The PeriOperative ISschemic Evaluation (POISE) study reported a reduction 
in peri-operative cardiovascular death following the administration of metoprolol in patients 
with or at risk of atherosclerotic disease and undergoing non-cardiac surgery. 144 However, 
the study protocol did not include routine peri-operative cardiac troponin measurement and 
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was underpowered to assess for sub-group analysis i.e. patients undergoing major vascular 
surgery.  The Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress 
Echocardiography Study group (DECREASE) trial 1 reported a significant reduction in major 
cardiovascular events following the administration of peri-operative bisoprolol. 145 The study 
is limited through the utilisation of CK-MB as the marker of myocardial injury as opposed to 
cardiac troponin resulting in a likely underestimation of the incidence of myocardial injury. 
The only trial to employ routine peri-operative cardiac troponin assessment following major 
infra-renal vascular surgery is the Perioperative !-Blockade (POBBLE) trial. 146 This trial 
reported one third of patients suffered peri-operative myocardial ischaemia and that peri-
operative !-blockade did not reduce the 30-day major cardiovascular event rate. The study 
protocol required a combination of cTnT >0.1ng/ml and persistent ECG ischaemic changes 
before the diagnosis of myocardial injury could be inferred. Landesberg et al demonstrated 
that even isolated minor elevations in post-operative cTnT (>0.03ng/ml) levels independently 
predicted a two-fold increase in mortality following major vascular surgery. 136 Thus, the 
POBBLE trial may be underestimating the actual incidence of clinically significant 
myocardial injury in the study population. Only Rajagopalan et al have reported the 
relationship between peri-operative !-blockade and isolated peri-operative cTnI levels in 
patients undergoing major vascular surgery. 143  This longitudinal observational study 
reported the incidence of peri-operative cardiac troponin rise was not affected by peri-
operative !-Blockade.  
The aetiology of peri-operative myocardial injury is complex. Traditionally it has been 
thought that prolonged myocardial stress in the setting of coronary artery atherosclerotic 
disease combined with plaque rupture account for the majority of peri-operative myocardial 
ischaemic events. However, as demonstrated in the current study, the resultant peri-operative 
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hypercoagulable state following major vascular surgery may also contribute to the 
development of myocardial injury in the peri-operative period. This may partially explain 
why pre-operative stress testing is relatively inaccurate for predicting post-operative 
myocardial ischaemic injury. 147  
During open infra-renal AAA repair cross-clamping of the aorta places considerable strain on 
the myocardium by dramatically increasing systemic vascular resistance and arterial pressure. 
148 It is thought !-blockade attenuates this physiological response by lowering the heart rate 
and improving coronary artery diastolic perfusion thereby reducing myocardial stress and 
improving myocardial oxygenation. During EVAR the infra-renal aorta is rarely totally 
occluded, thus any benefit inferred by the peri-operative use of !-blockade during open AAA 
repair may be negated in patients undergoing EVAR. To date no study has investigated the 
effects of peri-operative B-blockade on myocardial injury as defined by elevated post-
operative cardiac troponin levels in patients undergoing EVAR. 
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APPENDIX 1 
Classification of Endoleak 
Type-I:  Failure of stent-graft to seal against the aortic wall proximally (type-Ia) or 
against the iliac arteries distally (type-Ib) 
Type-II:  Retrograde blood flow through one (type-IIa) or more (type-IIb) normal 
branches of the excluded aortic segment e.g. inferior mesenteric artery or lumbar arteries. 
Type-III:  Structural failure of the stent-graft secondary to fabric disruption (type-IIIa), 
separation of modular components (type-IIIb), suture holes in fabric (type-IIIc) 
Type-IV:  Caused by graft porosity typically identified at the time of stent-graft 
deployment. 
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APPENDIX 2: LOST SAMPLES 
 
 
  
  A       B 
 
Unfortunately due to the departments research freezer being turned-off by a member of the 
domestic services department the majority of the initial patient cohort plasma samples (figures 
A & B) were invalidated prior to batch analysis.  
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APPENDIX 3:  PATIENT INFORMATION LEAFLET 
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APPENDIX 4:  PATIENT CONSENT FORM 
 
 
Coagulation, Endoleak and Myocardial  
Injury after EVAR (CEMIE Study)  
Consent Form 
 
Authorisation and Signatures 
 
 
I,________________________________, have been invited to participate in a study (The 
CEMIE study) investigating the short term changes to coagulation (clotting) following my 
endovascular aneurysm repair under the direction of Mr DJ Adam, in which I voluntarily 
consent to participate. 
 
a. The implications of my voluntary participation in this study, its nature, the duration, 
the purpose, the methods and means by which it is to be conducted, and the hazards which 
may be expected have been thoroughly explained to me by  
 
Mr Robert Davies 
 
b. I have read and understand all the written materials that have been provided to me 
describing this study and its potential risks and benefits. 
 
c. I have been given an opportunity to ask any questions I wish concerning the 
procedures, and all such questions have been answered to my complete satisfaction. I 
understand that my participation in this evaluation can be terminated at any time upon my 
request. 
 
d. I agree to allow authorised personnel to examine my medical Records and understand 
that this will be done in the strictest confidence. 
 
Date  ________/_________/________ 
    Day        Month    Year  
 
_______________________    _______________________ 
Patient signature     Patient name printed 
 
_______________________    _______________________ 
Doctor Signature     Doctor name printed 
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APPENDIX 5: GP LETTER 
 
 
 
 
                                                                                 
  
 
Dear Sir/Madam 
 
 
I am writing to inform you that your patient_______________________ has agreed to 
participate in the following study: 
 
Coagulation, Endoleak and Myocardial Injury after EVAR (CEMIE Study)  
 
The study involves obtaining peri-procedural blood samples (10-20ml) to assess altered 
haemostasis and myocardial injury. The study does not involve any new therapeutic 
pharmacotherapy or modality and will not influence the clinical treatment of your patient. 
Your patient will be followed up during their routine clinic appointments where possible. 
 I have enclosed an information sheet providing additional information. Should you have any 
queries please feel free to contact me. 
Kind regards 
 
Mr. Robert Davies 
Vascular Research Fellow 
Patient Sticker  
Here 
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